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Abstract 
Non-motor Parkinson’s Disease (PD) symptoms are substantial factors of PD arising 
throughout disease stages, yet their diagnosis and monitoring remain a challenge. Sensory 
abnormalities in PD occur across sensory systems and disease stages, contributing to disease-
related impairments. However, the extent of symptoms is unknown, with inadequate 
monitoring and treatment options furthering disease management difficulties. The current work 
studies movement-independent visual perceptions of time, displacement and velocity in PD 
patients across disease stages using levodopa, deep brain stimulation (DBS), or no PD therapy. 
Perceptual tasks were conducted using a computer-generated graphical device designed with a 
focus on simplicity and flexibility. Perception of all tested visual modalities was impaired in 
PD (often extending to early PD stages), with negligible levodopa and DBS induced 
improvement. The observations help explain visuospatial, visual recognition and timing 
deficits occurring in PD while providing potential disease markers, and validates the graphical 
tool’s usefulness for disease diagnosis and monitoring.      
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Lay Summary 
Parkinson’s disease (PD) is one of the most common movement disorders in Canada, affecting 
over 100, 000 Canadian residents, leading to an economic burden of over $120 million a year. 
Although the movement-related symptoms are the most commonly known, non-motor 
symptoms are also widely present in the disease throughout all stages, and are commonly 
reported to be the more significant contributors to deficits in patient quality of life. The primary 
focus of treatment however is still directed at the motor symptoms, with available therapies 
and diagnostic procedures primarily targeting these motor symptoms. Furthermore, the extent 
of non-motor symptoms has yet to be discovered. Due to the disease symptoms presenting 
themselves differently on an individual basis, and numerous non-motor symptoms arising early 
in the disease (sometimes before motor symptoms) optimized patient treatment does not occur 
in many cases. Based on the above, this thesis aims to study select visual non-motor 
phenomena, to examine their potential dysfunction in PD, as well as their potential use for 
disease monitoring and diagnostic procedures. This thesis analyzes the visual perception of 
time, displacement and velocity in individuals with PD, the effect of common pharmaceutical 
(levodopa) and non-pharmaceutical (deep brain stimulation) therapies on these perceptions, 
and the use of a computer-generated graphical tool to analyze the said perceptions. It was found 
that all of the studied perceptions were abnormal in PD, even at the early stages of the disease. 
Furthermore, the tested therapies did not appear to improve these perceptions, with levodopa 
potentially having a detrimental effect on temporal and velocity perceptions.  The use of the 
graphical software was validated throughout the studies and was shown to be a potential 
disease monitoring and diagnostic tool that can be easily implemented in clinical and non-
clinical settings to aid disease management. Furthermore, the findings regarding the studied 
perceptual dysfunction occurring independently of movement provides further insight into 
non-motor PD abnormalities, while helping to explain the phenomena of timing, spatial, and 
object recognition deficits occurring in PD. 
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Tell me and I forget. Teach me and I remember. Involve me and I learn. 
 
- Benjamin Franklin (Traditional Chinese proverb) 
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Chapter 1  
1  Introduction  
This chapter will provide an overview of the Parkinson's Disease (PD) symptoms, 
with a focus on non-motor abnormalities occurring in PD. A specific focus will be on visual 
perceptions of time, displacement and velocity, reviewing what is currently known 
regarding the effect of PD on these symptoms. Furthermore, this section will provide a 
brief outline of levodopa (L-dihydroxyphenylalanine) and deep brain stimulation (DBS) 
therapies, and their effect on non-motor symptoms of PD. 
1.1 Background 
PD is the second most common neurodegenerative disorder in Canada, affecting over 
100,000 residents and leading to an annual economic burden over $120 million [1]. The 
incidence of PD in Canada is growing (projected to affect 164,000 individuals by 2031) 
[1], the lack of prevention methods and long-term management treatments emphasize the 
significance of this neurological puzzle for Canadians and the country as a whole [2]. PD 
has been considered a movement abnormality since its 19th century description by James 
Parkinson, in which he specified motor symptoms such as bradykinesia, resting tremor, 
muscular rigidity and impairments of posture and gait [3].  However, Dr.  Parkinson also 
noted that non-motor abnormalities including sensory, mood, autonomic and sleep 
disorders commonly affect those with PD [4]. It was later determined that many major PD 
symptoms are rooted in the death of dopaminergic neurons in the substantia nigra pars 
compacta (SNc), leading to abnormal basal ganglia (BG) functioning [5]. Although a 
greater focus has been given to motor symptoms of the disease in the past, non-motor 
symptoms substantially contribute to decreased quality of life (often to a greater extent than 
motor symptoms) [6–8], increased economic burden [9, 10] and increasing the rate of 
patient institutionalization [11]. 
Current approaches to PD treatment focus on alleviating motor symptoms, 
appearing to be inadequate for treating many non-motor disease symptoms [12]. Levodopa, 
a first line pharmaceutical PD therapy, appears to have a variable effect on non-motor 
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symptoms, though beneficial effects are often seen with regard to motor impairments [4]. 
Subthalamic DBS, a promising late-stage PD treatment involving electrical stimulation of 
the BG generally elicits similar therapeutic effects as levodopa; however, its effect on non-
motor symptoms are still relatively unknown [13]. Although the burden of the non-motor 
symptoms of PD are substantial there is a current lack of adequate treatment methods. 
However, there is growing evidence that many non-motor symptoms arise before the 
development of motor symptoms—sometimes by years [14]—making them promising 
targets for early diagnosis of PD or helping to identify at risk populations. We have 
conducted perceptual analysis of three visual modalities (time, displacement, and velocity), 
and designed a computer-generated graphical tool to assess individual ability for these 
perceptions. It is our hope that the work in this thesis will lead to the development of 
software capable of assessing some non-motor aspects of PD to help provide better 
treatment to those suffering, while also assessing certain perceptions and how they are 
affected by PD as well as levodopa/DBS. 
1.2 Parkinson’s Disease Epidemiology and Pathophysiology 
This subsection will provide an outline of the scope of PD and how great of an influence 
it has on humanity, as well as a summary of the neural basis for PD to improve 
understanding of the neurophysiological concepts discussed in later chapters.   
1.2.1 Prevalence and Incidence 
PD is the most common movement disorder involving progressive neurodegeneration of 
the central nervous system [15]. There is currently no method to cure or stop the disease 
progression [2]. General estimations regarding PD’s prevalence is 1–2 cases per 1000 
people in unselected populations [16], with approximately 1% of people over the age of 60 
suffering from the disease [17]. There prevalence of PD in North America is between 111–
329 cases per 100 000 [18]. There is large variance seen in the reported PD incidence, 
which may be due to methodological differences in the diagnostic criteria and means of 
attaining PD status; most reports however show around 10–20 individuals per 100,000 to 
develop PD [15]. Early-onset development of PD (before the age of 50) is rare, only 
occurring in 4% of cases [19]. Studies focusing on the incidence of "at risk" populations 
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(individuals above 55 or 65) showed PD incidence rates to be 410–529 persons per 100,000 
[24]. Age is the greatest risk factor for PD development, as the diseases incidence increases 
in an exponential fashion, peaking at 80 years of age [20].  
1.2.2 General Pathology 
The primary pathological symptom of PD is the progressive loss of dopaminergic neurons 
in the SNc, which project to the putamen through the dopaminergic nigrostriatal pathway 
[21], with past work showing an approximate 75–95% post-mortem reduction in SNc 
neurons in PD patients compared to age-matched controls [22]. However, degeneration of 
SNc neurons occurs in substantial volumes early in the disease as well [23]. The moderate 
to severe loss of dopaminergic neurons in the SNc likely leads to the motor symptoms 
typical in PD, especially those involved with reduced movement [24]. Neural degeneration 
occurring in PD is not contained to the SNc, with cellular degeneration occurring in regions 
such as the hypothalamus, amygdala, raphe nucleus, locus coeruleus, and the dorsal motor 
nucleus of the vagus [21]. 
Another hallmark of PD is Lewy pathology, where mutations to the SNCA gene 
lead to misfolded α-synuclein proteins [2]. The misfolded α-synuclein proteins are 
insoluble, causing aggregation and the formation of inclusions in the neuronal cell body or 
cell processes (Lewy bodies and Lewy neurites respectively) [21].  Lewy body pathology 
is not limited to the neurons of the brain, with protein aggregations occurring in the spinal 
cord and peripheral nerves as well [2, 25, 26]. It has been suggested via the Braak model 
that PD occurs in 6 stages involving Lewy pathology, with the peripheral nervous system 
being affected first (pre-motor stages 1–2), followed by caudal (brain stem, olfactory bulb) 
brain regions (stage 3: motor features caused by nigrostriatal dopamine deficiency), and 
lastly the rostral (frontal) portions of the brain being affected (stage 4 - 6: advanced disease 
with increased non-motor symptoms arising) [27]. Although the Braak model provides a 
good explanation for the development of non-motor symptoms related to cognitive 
impairment occurring in late stage PD [28, 29] and other non-motor abnormalities 
occurring at early PD stages such as olfaction and constipation [30], further studies are still 
needed to confirm the Braak model for other non-motor symptoms [2]. Furthermore, not 
all PD patients display Lewy pathology, suggesting PD neurodegeneration to be more 
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complex than simple Lewy pathology involving protein mutations beyond those affecting 
α-synuclein [31, 32]. 
1.2.3 Classical Model of Basal Ganglia Function in Parkinson’s 
Disease 
The BG is a group of interconnected neuronal nuclei primarily consisting of the striatum, 
globus pallidus pars interna (GPi), globus pallidus pars externa (GPe), substantia nigra pars 
reticulata (SNr), the subthalamic nucleus (STN) and the SNc [33]. The neurotransmitter 
released from the projections of the GPi, GPe, striatal and SNr neurons is the inhibitory 
gamma-aminobutyric acid (GABA), whereas the STN projections release the excitatory 
neurotransmitter glutamate [34]. The motor cortical areas involved in BG circuits also 
release excitatory neurotransmitter (glutamate) which acts on other regions of the BG [35]. 
Lastly, the SNc neurons release the neurotransmitter dopamine, which can have either 
excitatory or inhibitory effects based on the nuclei it acts on [33]. There are other 
neurotransmitters released in the BG, however they are of little importance to the study of 
BG function in PD. The BG projects to the thalamus, where further projections to the higher 
neural areas of the cortex occur [36]. Although the BG has great importance with motor 
behaviour, it is involved in many other processes ranging from timing to learning and 
memory [37, 38]. 
The classical model used to describe BG neuronal pathway loops generally refers 
to the BG’s motor function and involves both a direct and an indirect pathway. This motor 
circuit best describes the BG’s function and dysfunction in relation to movement disorders 
[35].  As can be seen in Figure 1.1, motor areas of the cortex project to dorsal parts of the 
striatum (i.e. the putamen) via excitatory connections using glutamate. The neurons of the 
striatum enact an inhibitory response on the output nuclei of the BG (primarily the GPi and 
SNr) via a direct and indirect pathway. Striatal neurons involved in the direct pathway 
project GABA directly to the GPi and SNr, inhibiting their projections (which are also 
inhibitory) to the thalamus (which has connections with the cortex), thus closing the loop 
[35]. The striatal neurons involved in the indirect pathway elicit an inhibitory response on 
the GPe, which in turn has inhibitory projections to the STN. The connections from the 
STN however are excitatory, and project to the GPi and SNr which project to the thalamus 
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and finally back to the cortex. Thus, the direct pathway leads to an inhibition of GPi and 
SNr activity, while the indirect pathway is excitatory for these nuclei [35]. The balance of 
activity from the direct and indirect pathways are modulated by dopamine, released by SNc 
neurons projecting onto the thalamus. Striatal neurons involved in the direct pathway 
contain dopamine D1 receptors, where-as those involved in the indirect pathway have 
dopamine D2 receptors, leading to striatum neuronal excitation and inhibition respectively 
[35]. Direct glutaminergic connections from the cortex to the striatum also exist, causing 
excitation of the striatum and providing further central influence on the BG loop (Fig. 1.1). 
 
Figure 1.1: BG circuitry in normal and PD states 
Summary of the current motor circuitry model of the cortico-BG-thalamus loop. Pointed 
arrows signify excitatory projections and blunted arrows inhibitory, with the thickness of 
the line being proportional to the projection’s strength. a) represents the circuits 
functionality in normal states, with b) showing alterations that occur during PD. For both 
a) & b), the direct pathway involves dopaminergic modulation (from SNc projections) of 
the D1 receptor to the output nuclei, with the indirect pathway involving dopaminergic 
modulation (from SNc projections) of the D2 receptors to the GPe. In the Parkinsonian 
state reduced SNc neurons lead to reduced dopaminergic attenuation of both indirect and 
direct pathway, causing hyperactivity of the STN and the output nuclei. 
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PD causes large quantities of neuronal death to occur in the SNc, leading to depleted 
amounts of dopamine modulating the striatum over time. This in turn leads to increased 
activity of the GPi and SNr, causing increased inhibition of the thalamo-cortical and 
brainstem motor systems (Fig. 1.1) [35]. This BG model accounts for the occurrence of 
bradykinesia (slow movements), akinesia (lack of movement), and difficulties in 
movement that occurs in PD. The use of levodopa or dopamine agonist pharmaceuticals 
(which act to restore neural dopamine levels) help to restore normal BG function to 
effectively reduce movement abnormalities occurring in PD patients. An undesirable side 
effect of levodopa medication however is sporadic movements known as dyskinesia. The 
classical BG model explains that this phenomenon is caused by excessive inhibition of 
striatal neurons projecting to the GPe, causing less inhibition of the GPe, then over-
inhibition of the STN (reducing its activity), in turn decreasing the activity of the GPi and 
SNr output neurons.  This leads to excessive activity in the cortical motor areas, and 
sporadic dyskinetic movements [35]. The outcome of DBS to the STN is also accurately 
described by the classical BG model. As DBS causes an ablation effect on the neural region 
it acts on, using it on the STN reduces this nuclei’s activity which is overexcited in PD, 
thus helping to restore proper activity levels of the GPi and SNr and improving the 
movement symptoms of PD [35, 39]. DBS of the GPi works in a similar fashion as STN 
stimulation [36]. Though the classical model of the BG is not perfect, it does a good job of 
simply and elegantly providing a basis for BG function in healthy and disease states, as 
well as the effect of different therapies [36]. 
1.3 Current Parkinson’s Disease Treatment 
A major complication of PD treatment is that there are currently no therapy options 
available that significantly slow or stop the progression of PD. Due to the heterogeneous 
nature of the disease it appears that no given singular treatment will be capable of "curing" 
PD; however, it is likely that future treatments will offer individualized therapies based on 
the symptoms and needs of a given patient [2]. Although there are yet to be preventative 
treatments or cures for PD, there are still methods for treating the symptoms of PD, with 
the aim of improving the lives of the patients suffering from the disease. 
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1.3.1 Pharmacological PD Treatment 
The first-line treatment for PD has classically been, and continues to be drugs which 
enhance intracerebral dopamine concentrations or activate dopaminergic receptors, such as 
levodopa (which is capable of crossing the blood-brain barrier (unlike dopamine) before 
being converted to dopamine),  dopamine agonists,  monoamine oxidase type B inhibitors 
and amantadine [40, 42]. Due to the current inability of PD therapies to cure or slow the 
progression of the disease not all patients begin treatment right away. Therapeutic 
intervention typically begins as soon as symptoms become problematic for the patient to 
attempt to improve quality of life [2]. Many movement related abnormalities arising early 
in the disease progression like bradykinesia and muscular rigidity are treated well with 
dopaminergic treatments, while monoamine oxidase type B inhibitors only cause marginal 
improvements, making dopaminergic drugs the primary pharmaceutical intervention when 
symptoms are more severe. The effect of dopaminergic treatments is more variable for 
disease related tremors; however anti-cholinergic drugs can be effective for this symptom 
[2]. 
 Use of dopaminergic drugs (especially dopamine agonists) is however not without 
cost, with adverse reactions such as nausea, daytime sleepiness and excessive fluid 
retention in parts of the body. Furthermore, dopaminergic medications can lead to impulse 
control issues, seen through excessive gambling, eating, spending, and hypersexuality.  The 
occurrence of visual hallucinations is also a common side effect of dopaminergic treatment 
[2].  As dopaminergic therapies generally are the most successful at alleviating motor 
complications in PD, and levodopa has a lower risk of side effect development, it is 
generally used as a first-line PD treatment [2, 41]. Levodopa use is not without fault 
however, as prolonged use can lead to motor complications involving motor fluctuations 
while using the medication (ON periods: levodopa is functioning as intended; OFF periods, 
levodopa is not functioning as intended, leading to severe motor symptoms) as well as 
sporadic "dyskinetic" movements [2]. Due to these complications, levodopa use is often 
refrained until necessary, or used sparingly while coupled with monoamine oxidase type B 
inhibitors or dopamine agonists (though the believed benefits are not yet validated) [42, 
43]. Some non-dopaminergic pharmaceuticals are used to treat specific non-motor 
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symptoms of PD. Clozapine is commonly used to treat psychosis. However, there is a 
minute risk of a deadly adverse drug reaction (affecting 0.38% of patients) necessitating 
regular monitoring or the use of the much less effective Quetiapine [44]. Interestingly, the 
use of cholinesterase inhibitors by PD patients with dementia can lead to reductions in 
visual hallucinations and delusions, with specific selective serotonin agonists appearing to 
reduce psychotic symptoms without altering motor function [45, 46]. 
Motor fluctuations, dyskinesia and psychosis associated with long term use of 
dopaminergic medication signifies the progression of PD to advanced stages, further 
reducing patient quality of life.  It is believed that motor fluctuations and dyskinesia might 
be caused by the late stage occurrence of pulsatile stimulation of striatal dopamine 
receptors, brought on by decreased striatal dopamine levels [2].  Combining previously 
mentioned pharmaceutical compounds with levodopa are common means to reduce the 
side effects of such treatments, with slow releasing dopaminergic medication currently 
being developed with hopes to reduce OFF motor fluctuations [40, 47]. An alternative 
method of achieving consistent blood-levodopa levels is to inject a concentrated levodopa-
carbidopa gel into the small intestine via a portable pump, which shortened OFF duration 
(lengthening ON durations) in late stage PD patients without dyskinesia [47]. Treatments 
that elicit effects on multiple neurotransmitter systems such as amantadine and clozapine 
often effectively treat dyskinesia, with pharmaceuticals containing nicotinic or 
serotonergic properties potentially acting as treatments for drug induced motor 
complications as well [40, 48]. The efficacy levodopa has towards late-stage PD symptoms 
(motor and non-motor) is generally poor, suggesting these symptoms are caused by 
abnormalities in other neurotransmitter systems [48]. Accordingly, some cholinesterase 
inhibitors have been shown to be effective in the treatment of dementia and reductions in 
falls [49, 50]. As can be gathered from the above, the optimal treatment of PD using 
pharmacological agents is a difficult task requiring personalized therapeutic approaches. 
1.3.2 Deep Brain Stimulation 
The discovery of lesion-like effects occurring from high-frequency DBS led to its clinical 
use in treating neurological disorders through selective neural targeting (Fig. 1.2).  High-
frequency DBS of the STN (and less frequently the GPi) significantly improves 
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bradykinesia, rigidity, and tremor, decreasing the patient’s average levodopa dose use by 
60% [39, 51]. This reduction in levodopa use in turn reduces its undesirable side-effects, 
further improving patient quality of life [52]. Surgical teams use magnetic resonance  
 
Figure 1.2: DBS of the Subthalamic Nucleus 
Pictorial representation of DBS to the STN. A generator located sub-dermally at the chest 
generates electrical pulses which are transferred to the electrode which is in contact with 
the STN. The electrode is at the tip of a lead that was surgically implanted into the brain. 
The electrical pulses alter neuronal activity, and when controlled properly (based on 
location that the pulses are received, and the electrical current being used) provides 
therapeutic effects to the receiving individual. 
 
imaging (MRI) localization to choose the implantation target, although errors can occur 
due to MRI distortion and brain expansion (due to reduced intracranial pressure from the 
drill hole). DBS can be administered unilaterally (to one side of the brain only) or 
bilaterally, depending on the patient’s affected neural areas. Although it is not fully 
understood, it is believed DBS functions as an ablation by jamming neural messaging, 
inhibiting neural firing, and through inhibition of some neurotransmitters and hormones 
[53–55]. Patients are considered for surgery based on what stage of the disease they are at 
(with late stage patients being prioritized in Canada) and if the symptoms DBS successfully 
improves are present. DBS is not an effective treatment for cognitive deficits and dementia, 
10 
 
and in fact often worsens it due to the trauma occurring during surgery.  Furthermore, DBS 
typically functions in a similar fashion to Levodopa when considering the efficacy of the 
therapy on an individual [56]. 
When comparing PD symptom severity with the DBS turned ON vs. OFF there was 
substantial improvements seen ON DBS, analyzed using the Unified PD Rating Scale 
(UPDRS) [39]. The UPDRS is made up of 4 examinations; section I– mental and cognitive 
changes (including mood); section II– changes in daily living activities; section III– motor 
symptoms; section IV– therapeutic complications, sensory systems, fluctuations and 
dyskinesia [39]. The UPDRS is the current gold standard diagnostic examination for the 
assessment of PD symptom severity and quality of life and has been validated through 
countless studies [39, 57].  Patients in a DBS ON, Drug OFF state had 50% and 52% 
increases in section II and section III UPDRS scores respectively compared to their pre-
operation scores, with DBS additionally providing a 23% improvement in PD symptoms 
compared to ON medication patients [58, 59].  The efficacy of STN DBS experiences 
modest reductions over time, in contrast to levodopa’s significant efficacy deterioration 
[60–62]. Tremor improvements were seen with up to 70% reductions, along with a 50% 
improvement in akinesia [63]. Reductions in dystonia, improved postural stability and gait 
are other positive outcomes of DBS use [39]. DBS induced neural plasticity and reduced 
levodopa use leads to major dyskinesia reductions (with reported reductions as great as 
70%), substantially improving patient quality of life [39, 63, 64]. Motor symptoms are 
however only mildly improved (or not at all improved) when using DBS compared to ON 
medication states, however reductions in medication use leads to the previously discussed 
benefits, compounded by stable therapy [39]. Long-term DBS use sees PD symptoms 
progressing in a "natural" way, suggesting that extended use does not have side effects 
[65]. 
The use of DBS is not without risk and side effects, many of which arise from 
surgical complications. Although reported data differs considerably between reports, one 
study analyzing 526 patients saw that 3.4% of DBS implantation surgery resulted in 
asymptomatic hemorrhages, 4.4% in transient symptoms, and 0.6% caused permanent 
symptoms in patients. As 2–4% of cases have severe adverse effects from surgery (mainly 
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due to intracranial hemorrhage) pre-operative MRI’s are critical for operation success 
through planning the implantation around blood vessels and non-targeted neural regions 
[59]. Non-permanent complications such as post-operative confusion (in around 10% of 
patients) can arise due to small intracranial contusion (bruising), minimal bleeding, or 
uncontrollable factors like prolonged open brain surgery and dopaminergic drug 
withdrawal [63, 66]. Although surgery related infections and complications sometimes 
occurring, as well as complications with the receiving of DBS, these are generally non-
severe and treatable [39]. Cognitive impairments such as sadness, (hypo)mania, hilarity, 
impulse aggressive behaviour disorder can develop in the post-operative stage, however 
they tend not to persist [39].  Although apathy and depression might be associated with 
receiving DBS surgery, the most common chronic cognitive change is declines in word 
fluency [67–68]. It should be noted that these cognitive alterations were not seen in younger 
and non-demented patients [39]. Cognitive decline does generally occur over time (or is 
accelerated) with DBS-STN use, which can lead to impulsive decisions and dementia [96, 
71]. There are many advantages to DBS over medication alone, and both appear to have 
the same occurrence of adverse events. However, it seems there is a greater occurrence of 
serious adverse events in those receiving DBS (though most are related to incorrect 
implantation or hardware failure) [58, 72].  Although there are risks involved with DBS 
use, they are typically not severe, and stimulation generally provides large improvements 
over medications for appropriate patients. 
1.4 Symptoms of Parkinson’s Disease 
Although some symptoms are commonly attributed to PD, such as tremor, bradykinesia, 
and freezing of gait (FOG), the extent of abnormalities that could arise in patients with PD 
is vast, with no patient displaying every phenotypic trait of the disease. However, 
regardless of the symptoms occurring in a given PD patient, overtime these symptoms 
usually worsen, with many posing substantial detriment to patient health and quality of life. 
1.4.1 Parkinson’s Disease Motor Symptoms 
Although PD was not truly defined until work conducted by James Parkinson’s in the 19th 
century, the classic motor symptoms were described much earlier in Indian and Chinese 
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texts dating back to approximately 1000 BC [3]. These classical symptoms include rest 
tremor, muscular rigidity, bradykinesia, akinesia and postural and gait impairments [2]. 
Further motor symptoms such as softness of speech, impairments in handwriting and 
difficulties with swallowing are examples of other symptoms that could arise in the disease 
[3, 73]. These motor symptoms present in an asymmetrical or heterogeneous manner, 
leading to two major PD subtypes: tremor-dominant PD (generally with other motor 
symptoms being mild) and non-tremor-dominant PD (generally involving akinetic or rigid 
movements and impairments of gait and posture) [2]. Additionally, a hybrid or 
indeterminate subgroup exists where patients display several motor disease phenotypes of 
similar severity [2]. Interestingly, the disease subgroups might have different pathogenesis 
and causes, as well as the tremor-dominant subtype of the disease often progressing slower 
and causing less functional disability compared to non-tremor subtypes [74, 75]. 
As PD motor features are typically linked to dopaminergic disorder, typical first 
line treatment of PD involves the use of dopamine replacement agents such as levodopa. 
When initially used in proper doses, levodopa elicits large improvements over the classical 
motor symptoms of PD. However, after 5 years of levodopa use 75% of PD patients no 
longer receive stable and effective treatment from the medication [76]. Although from a 
clinical standpoint levodopa appears to slow the progression of PD motor symptoms, 
neuro-imaging studies show its use led to accelerated decay of nigrostriatal nerve terminals, 
further questioning the drugs long term use [77].  DBS of the STN has become the gold 
standard for advanced-stage PD surgical procedures. However, as previously discussed, 
DBS use is not without flaws as post-surgery complications as well as stimulation of non-
targeted neural regions can have negative side effects for the patient receiving the therapy 
[39]. 
1.4.2 Parkinson’ Disease Non-Motor Symptoms 
Though motor abnormalities and reduced dopamine levels are typical clinical markers of 
PD disease, non-motor PD symptoms arise at all disease stages with some frequently 
arising prior to motor symptoms [78].  Unlike motor symptoms, many non-motor disease 
symptoms are not caused by dopamine deficiency, and instead are related to deficiencies 
of different neurotransmitters [78]. Accordingly, most non-motor symptoms do not 
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respond well to current PD treatment methods, making the management of these symptoms 
a major challenge in the treatment of PD. The non-motor features of PD are widespread, 
and (like motor features) asymmetrical, ranging over multiple classes of impairment. Here 
we will describe some of the non-motor features of PD, however it should be noted that 
this is not a comprehensive review, with notable abnormalities such as sleep disorders and 
autonomic dysfunction not being reported.  
1.4.2.1 Neuropsychiatric Features 
The neuropsychiatric features of PD can be present early in the disease’s progression (at 
the pre-motor phase), persisting into late stages, fluctuating with the ON-OFF motor states 
[4]. A common neuropsychiatric feature of PD is anxiety, affecting up to 60% of patients 
[79]. These anxieties include general anxiety, social phobias, panic attacks, and are 
frequently (but not always) accompanied by depression [80, 82]. Anxiety is associated with 
low dopamine levels, accordingly, pharmaceutical dopamine replacement and DBS both 
reduce depressive symptoms, however this is not necessarily entirely due to reduced 
anxieties as improvements in motor functions may also play a role [82, 83]. As anxiety 
(and the associated depression) often arise before motor symptoms, these symptoms may 
encompass pathologies beyond SNc degeneration [84]. 
As previously mentioned, depression commonly affects individuals with PD, being 
clinically significant in 35% of patients. Although PD related depression is generally a 
milder form than depression in non-PD individuals, it is more commonly accompanied by 
apathy and anhedonia [85].  Although depression can arise at all stages of PD, it displays 
correlations with duration of disease, motor severity, motor fluctuations and dosage of 
dopaminergic replacement medication [86]. Depression in those with PD may be a 
symptom of PD pathology, reactionary to PD related disabilities, an individual 
phenomenon or a combination of the three, making it a complex problem and explaining 
why only some benefit from dopaminergic therapy [87]. Both individuals with and without 
PD suffering from depression show alterations to the dopaminergic, serotonergic and 
noradrenergic systems [88]. Although there is considerable evidence for alterations to the 
dopaminergic and noradrenergic systems in those with PD depression compared to PD non-
depressed patients, there are confounding results regarding serotonergic function being a 
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factor in depression development in PD [88–101]. Anti-depressive medication targeting 
the noradrenergic system appears to be the most effective medication for the treatment of 
PD related depression [92]. 
Dementia and cognitive dysfunction commonly affect individuals with late stage 
PD; though this may be caused by natural aging processes, up to 83% of late stage PD 
patients suffer from some form of cognitive decline [93]. Individuals with tremor-dominant 
PD are less susceptible to the development dementia than individuals with non-tremor-
dominant PD [94]. Late-stage PD dementia does not have a BG origin, but is related to 
Lewy body pathology of the cortical regions, with increased Lewy body/neurite mass 
correlating to increased severity of dementia [95]. Dopaminergic treatment poses little 
benefit and often worsens psychosis and hallucinations associated with PD dementia, 
however early cognitive impairments (such as impaired executive function) arising in 
early-stage PD appears to be dopamine dependent and may be improved by dopaminergic 
drugs [96–98]. Other symptoms of cognitive decline such as recognition and memory do 
not respond to these drugs, suggesting multiple neural pathways using different 
neurotransmitters are affected in PD [97]. Furthermore, too much or too little dopamine 
can lead to cognitive impairments, explaining why cognitive function varies throughout 
the stages of the disease and when using dopaminergic therapy [99]. 
Similarly to dementia, psychosis (generally presented through visual hallucinations 
and delusions) often arises in late stage PD, affecting 40% of patients [100]. MRI studies 
have revealed little difference in cortical structure between PD patients with and without 
psychosis. There are however alterations seen in the processing of visual stimuli, which 
may be further affected by reduced retinal dopamine levels caused by PD [101]. The use 
of dopamine therapies can lead to the development of psychosis in PD, and dopamine 
antagonists are in fact sometimes used to reduce the symptoms of psychosis [98].  
Processes utilizing acetylcholine are also implicated in the development of psychosis, with 
anticholinergic drug use aiding in the development of psychosis due to further impairments 
to cortical cholinergic transmission [102]. 
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1.4.2.2 Sensory Features 
Pain and somatosensory dysfunction are common sensory abnormalities of PD, affecting 
up to 80% of the patient population [103, 104].  Pain in PD can present as either nociceptive 
(occurring at peripheral pain receptors), or neuropathic (neurologically rooted) pain, and 
often fluctuates based on motor fluctuations (with it being worse in the OFF state) [103, 
105–107]. Nociceptive pain occurs in PD due to musculoskeletal dysfunction (for example, 
dysfunctions that lead to stiffness), with neurological pain having central origin and 
developing due to neurodegeneration [4]. Reduced levels of dopamine at the BG alter pain 
thresholds in PD patients, with dopaminergic medication increasing pain thresholds during 
ON periods [108]. However, since dopamine replacement therapy does not eliminate pain 
in PD there are likely other non-dopaminergic mechanisms involved in PD induced pain. 
As both the serotonergic raphe nuclei and the noradrenergic locus coeruleus brain regions 
are involved in the tuning of pain sensations and are pathologically altered in PD, they 
likely contribute to abnormal pain perception in PD [88]. Treatment primarily focuses on 
alleviating pain in the OFF periods with dopaminergic medications and other pain 
modulating drugs if needed. If painful dystonia is present and not aided by dopamine use 
then botulinum toxin injections may be used where the dystonia is present [4, 109]. 
One of the classical non-motor symptoms of PD is olfactory disturbances 
(presenting as hyposmia and anosmia), which develops in over 90% of PD patients and 
often arising before motor symptoms of the disease [88]. Hyposmia has often been 
considered a promising early biomarker of PD and is sometimes paired with other disease 
markers to assist in diagnosis [88].  As previously mentioned, early dysfunction of smell 
could be due to the spread pattern of Lewy bodies/neurites in PD starting at the medulla.  
However, olfactory dysfunction in late stage PD may be linked to cholinergic denervation 
and the onset of dementia and other cognitive deficits as well [88, 110]. Due olfactory cells 
being unchanged and reductions in the volume of the olfactory bulb neural region in PD, it 
appears that the abnormality has a central origin [111, 112]. There appears to be little to no 
disturbance of the dopaminergic and serotonergic neurons in the olfactory bulb and its 
associated nuclei, which corresponds to the lack of effect caused by dopaminergic 
medications [88, 113]. Although olfactory function appears to have promise in assisting in 
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clinical diagnosis of PD, our lack of understanding its pathological model impairs the 
understanding of olfaction’s relationship to PD progression [88]. 
1.4.2.3 Visual features 
Although a perceptual abnormality, visual disturbances occurring in PD are of particular 
importance to the work described in this thesis. Disturbances to visual processes are a 
common phenomenon in PD, affecting up to 78% of individuals with the disease [114]. 
Poor vision in PD often stems from poor visual acuity (especially low contrast acuity) as 
well as impairments in colour discrimination [115, 116].  Death of dopaminergic neurons 
in the retina may be the cause of poor visual acuity, however dopaminergic therapy has 
only moderate effects, suggesting other factors such as abnormal eye movements or 
blinking [117].  24% of patients also suffered from reduced visual fields (in the same 
fashion as glaucoma patients), suggesting PD causes reduced visual field size or increased 
risk of glaucoma development [118]. Deficits in oculomotor function (namely saccadic and 
smooth pursuit eye movement) are common visual symptoms of PD, affecting 75% of 
patients [119]. The maximum saccadic speed (rapid eye movement used to shift visual 
attention) in the horizontal plane and reaction times are slowed in PD, and patients often 
under-reaching their target. Furthermore, smooth pursuits sometimes involving choppy 
mini saccades as opposed to smooth movements [119, 120]. Smooth pursuit movements 
have been shown to be impaired at early stages of the diseases with evidence supporting 
the same trend for saccades. The dopamine reductions occurring at the BG are believed to 
be the cause of oculomotor deficiency [121, 122].  Patients sometimes suffer from 
nystagmus (repetitive uncontrolled eye movements) and difficulties with convergence for 
changing depth, which can result in blurriness and double vision [119, 123, 124].  
Furthermore, reductions in the frequency of blinking occurs during PD, leading to a staring, 
"mask face" appearance [125]. 
Visual impairments in PD extend to complex visual processes involving brain 
regions extending beyond the retina. Individuals with PD show deficits in visuospatial 
orientation, extending to difficulties determining what is vertical, proper positioning of 
body parts in space (proprioception), and conducting route-based walking tasks [126, 127].  
Deficits have also been seen in visuospatial working memory (which is selectively 
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impaired early in PD), possibly indicating the degeneration of the BG, dorsal visual stream 
and/or the frontal/prefrontal cortex [128]. The conduction of memory tasks involving 
specific spatial orientations, as well as orientation and motion discrimination is impaired 
in PD [128]. These task deficits in PD suggest that abnormalities in visual processing lie 
beyond retinal abnormalities due to involvement of higher visual centres [140]. The 
perception of face discrimination, as well as the ability to imagine a certain face is also 
abnormal in some PD cases [129]. Furthermore, perceiving certain emotions through facial 
recognition (especially negative emotions like anger) is disrupted in PD [130]. Patients 
with PD also can display difficulties staying focused on relevant goals for problem solving 
tasks involving visual stimuli [114].  Visual hallucinations can also arise chronically in PD, 
especially among individuals using levodopa or dopamine agonists [140]. One study saw 
40% of PD patients suffer from hallucinations within the last 3 months, with chronic visual 
hallucinations occurring in 22% of patients [131]. Severe cognitive dysfunction, disease 
duration and excessive daytime sleepiness are all predictors for the development of visual 
hallucinations, with even minor hallucinations increasing the risk of depression [114]. 
Numerous pathological changes affect the visual system of PD patients [114]. 
There are a few alterations when considering direct changes to the eye, with the most 
notable being the loss of neurons and dopamine in the retina, leading to reductions in retinal 
dopamine levels [132]. Dopamine is an important neurotransmitter in the retina, as it assists 
in the organization of cell receptor fields and modulates the activity of photoreceptors 
(which are responsible for converting light information to electrical information) [133, 
134]. Cell loss of the retina is the most severe in the peripheral regions; however, thinning 
of the optic nerve also occurs at the retinal fibre layer [132, 135]. In addition to retinal 
alterations, it has been shown in vitro that the iris is not able to contract to the same degree 
as the iris’ of healthy individuals [136].  Central visual abnormalities include abnormal 
energy availability of the primary visual cortex, as individuals with PD see glucose 
metabolism rates reduced by up to 23% [132, 137]. This compounded with reduced 
dopamine levels at the visual cortex, BG, and possibly superior colliculus could be the root 
of abnormal saccade production [138]. Furthermore, the BG is directly involved in saccadic 
eye movements which in turn have anatomical overlapping with smooth pursuits, possibly 
explaining why both are abnormal in PD [114]. Functional changes also occur at the fronto-
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striatal neural network and the temporal-occipital cortex which, can present early in PD, 
leading to impairment in memory tasks and problems [139, 140]. 
1.5 Perception of Displacement, Time, and Velocity 
A primary focus of this thesis is to analyze temporal, displacement and velocity visual 
perceptions in PD patients. The following section will look into the processing of these 
perceptions in healthy individuals, and what is known about their alterations in PD. 
1.5.1 The Perception of Time and Parkinson’s Disease 
The perception of time is a vital component of human life, necessary for navigation through 
space in today's fast paced world. Be it engaging in everyday activities from kicking a 
soccer ball to playing the piano or remembering to pick up a friend from the airport, 
accurate timing is necessary for many aspects of life. However, unlike other biological 
sensory systems, there are numerous neural mechanisms that function together and interact 
with other physiological systems. Here we will discuss neural timing mechanisms, as well 
as the known timing deficits present in PD. 
1.5.1.1 Functional and Neural Timing Mechanisms 
The perception of time does not occur uniformly across all magnitudes of time, with 
multiple systems being used to perceive various timing magnitudes and achieve different 
timing goals [141].  Circadian rhythms are timing mechanisms functioning over the range 
of 24 hours and are largely influenced by the daily light/dark cycles and the control of sleep 
and metabolic cycles [142].  Interval timing of the seconds-to-minutes range is involved in 
decision making, foraging and arithmetic involving multiple steps [141]. Millisecond 
timing is necessary for the accurate control of movements, as well as speech 
generation/recognition, and playing or dancing along to music [141]. These timing 
mechanisms of different magnitudes involve different neural mechanisms to achieve their 
separate goals. The suprachiasmatic nucleus of the hypothalamus being used for the 
circadian clock, coordinating the tissue-specific rhythms through mechanisms such as light 
input and social information (often used for mating periods) [143, 144]. Work investigating 
the neural mechanisms of timing appear to indicate two individual timing circuits. The first 
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being an automatic, discontinuous timing system working in the range of milliseconds that 
is processed by the cerebellum. The second timing system is continuous, controlled by 
conscious thought (requiring the individual’s attention), and is controlled by the BG and 
other interconnected neural regions [141]. Millisecond timing operations at the cerebellum 
are believed to be controlled through long term potentiation/depression and possibly 
intrinsic neural firing properties [141]. However, changes in the cellular activity during 
timing activities of monkeys were also found in the BG, thalamus, prefrontal cortex, and 
the premotor cortex [145]. Although this appears to indicate millisecond timing involves 
the use of many neural systems beyond the cerebellum, the involvement of the oculomotor 
and skeleton-motor effector systems are likely the cause for much of the observed 
involvement from other neural centres [145]. Interval timing uses a wider range of neural 
components, with it necessitating an intact striatum, but not cerebellum or suprachiasmatic 
nucleus; however, both the striatum and cerebellum may be activated simultaneously to 
control different performance aspects [141, 146, 147].  It should be noted that interval 
timing displays a scalar property in that time estimation errors are proportional to the 
magnitude of the estimated time (via a linear relationship) [146]. 
When considering the neuronal method for interval timing (which is the most 
focused physiological timing process), the most common classic internal clock model 
comes from the pacemaker-accumulator model (Fig. 1.3) [141, 149]. In this model, pulses 
are emitted at regular intervals by a pacemaker to be temporarily stored in the working 
memory via an accumulator [150, 151]. During the feedback (reward) stage, the number of 
pulses received from the accumulator for a given time duration is moved from the working 
memory to the reference memory [141, 152].  The number of pulses accumulated for the 
current subjective time are compared to the pulses stored from a past, remembered event 
to estimate the amount of time that has passed in a given situation. The pacemaker-
accumulator model has several advantages to its use: its simplicity encourages its use 
across many species and tasks; it separates clock, memory and decision stages (allowing 
for the mapping of each stage to a neural region and transmitter system); and its success in 
predicting testable timing hypotheses [152–154]. Pharmacological testing was the first to 
demonstrate that the clock stage (which is modulated by dopaminergic agents) and the 
memory stage (which is modulated by cholinergic agents) are separate neural entities [141, 
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152]. Although the pacemaker-accumulator model succeeds in many ways as an internal 
clock model, it is still unclear if it holds much relevance to the brain structures and neural 
mechanisms involved in interval timing. This is exemplified by the model’s implications 
of direct/exclusive connections between the speed of the internal clock and the dopamine 
system, which has been questioned by PD studies and inconsistencies seen in the effect of 
dopaminergic drugs, and dopamine’s involvement in processes beyond internal clock 
speed that affect temporal perception (such as attention) [141, 155–158]. 
 
Figure 1.3: Pacemaker-Accumulator Timing Model 
Summary of the pacemaker-accumulator timing model, in which a pacemaker is constantly 
emitting pulses at a constant rate. When a signal is given or attention is focused on timing 
tasks the switch is turned ON, after which the pulses for the time duration of interest are 
counted by the accumulator and stored in the short-term working memory. This 
information is compared to known time durations that have been stored in the reference 
memory, after which a decision is made regarding the length of the timing duration, 
allowing for its perception. 
 
 
Although the pacemaker-accumulator timing model has been very useful towards 
understanding the neural mechanisms underlying timing, it currently appears to have 
inaccuracies, namely the fact that the BG does not have an exclusive temporal processing 
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role. More current work shows the BG’s role in temporal processing is to monitor the 
thalamo-cortico-striatal circuit’s activity, and to detect certain working memory patterns 
[159–161]. To account for this, the striatal beat-frequency (SBF) model was designed to 
describe timing through the activity of thalamo-cortico-striatal loops, where timing 
depends on the coincidental activation of neurons of the dorsal striatum (which are believed 
to contribute to executive function and decision making) and cortical neural oscillators 
[145, 161, 162]. In this model cortical oscillators are synchronized to a particular timing 
task, changing cortico-striatal transmissions (through long-term potentiation/depression) 
and increasing striatal neuron sensitivity towards the detection of cortical oscillators of the 
specific pattern [163–166]. In the SBF model the dopaminergic neurons of the SNc and 
ventral tegmental area are responsible for the cortical oscillation synchronization and task-
dependent cortico-striatal transmission changes [141, 167]. It was shown that when a 
reward is expected at a certain time, the dopaminergic neurons display characteristic signal 
burst patterns at the time of the expected award, along with sustained activity throughout 
the timing interval [168]. Thus, the SBF model postulates that cortical oscillator 
synchronization is initiated through a dopaminergic burst at the beginning of the timing 
trial, with the sustained activity being caused by an attentional activation of the cortico-
striatal circuits. In this model, updates to the cortico-striatal transmission causes the 
dopaminergic activity burst which occurs at the time of expected reward (i.e. when the 
desired timing is completed) [169]. The SBF model of timing currently appears to an 
adequate model due to its mechanisms being consistent with the postulated neural regions 
involved with timing (frontal cortex and striatum), along with it importantly reproducing 
the scalar property of timing (necessary for accurately predicting human interval timing) 
[145]. Though there are still properties of the model that need to be addressed (namely 
similarities seen between counting and timing [141, 170]), it (alongside the imperfect 
striatal beat-frequency model) still shows great value in interval timing predictions for 
certain timing tasks and pharmacological (namely dopaminergic and cholinergic) 
intervention. 
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1.5.1.2 Basal ganglia and Dopaminergic Involvement in Timing, and 
the Effect of Parkinson’s Disease 
Although the exact neurological mechanisms of time perception are yet to be fully 
understood, it is clear that both the BG and dopamine play a substantial role in interval 
timing [145]. Past pharmacological and animal studies have shown dopamine agonists and 
antagonists to respectively speed up and slow down judgments of time [171]. Furthermore, 
animal studies indicate lesions to the SNc lead to improper timing that can be corrected to 
some degrees through levodopa use, implying the dopaminergic pathway’s importance in 
subjective timing [171, 172]. Animal studies also point to the BG as being a primary 
contributor to interval timing [172]. As PD leads to decreased neural dopamine levels and 
abnormal BG functioning studies regarding PD’s effect on timing have been used to 
increase knowledge on dopamine and the BG’s role in temporal perception. In 50% of time 
estimation studies and 67% of time production studies there were reported deficits in PD 
patients compared to control participants [172]. Levodopa appeared to improve temporal 
perception in some work; although this implies a role of dopamine in timing [172], there 
have been notable discrepancies in which PD patients perform the time perception tasks 
better when OFF levodopa [171, 173]. This might be caused by "dopamine overdose" in 
the frontal-striatal circuits involved in temporal processing as they may not be severely 
affected in early stages of PD. Thus, while the levodopa doses are optimal for correcting 
movement abnormalities, they are detrimental towards timing operations [174, 275]. 
Again, with time reproduction studies, there was not a uniform disruption seen in temporal 
reproduction for PD patients, with 67% of the studies showing PD related abnormalities 
(with the 71% of the studies that show timing differences in the PD also showing 
improvements from levodopa use) [172]. An interesting phenomenon that has been 
observed in PD patients during time reproduction tasks is the "migration effect", in which 
smalltime intervals are overestimated, and smaller intervals are underestimated [173]. With 
regards to temporal discrimination studies (the ability to differentiate stimuli from one 
another), 60% of the studies showed abnormalities in PD patients, with no studies showing 
improvements from levodopa, and one in fact showing medication-based impairments [38, 
172]. Based on past work PD appears to affect timing processes, however these temporal 
dysfunctions are not present in all timing tasks or for certain patient groups. Furthermore, 
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the majority of past work studying temporal perception in PD patients involves the use of 
the motor system, leading to confounding results regarding the observed dysfunction being 
potentially caused by motor or timing deficits. It is very likely that the BG and dopamine 
are involved in timing, as they are key components of the previously described models 
which best describe and predict timing currently, and due to the observed timing deficits 
in PD patients. The positive effect subthalamic DBS has towards improvements in timing 
tasks for PD patients further provides evidence for the BG’s role in temporal processing 
[172]. However, due to the deficits in attention, working memory and motor function 
occurring in PD [2, 176, 177], it is not fully understood what the root cause of timing 
impairment affecting PD patients is. 
1.5.2 The Perception of Displacement and Parkinson’s Disease 
Unlike temporal perception, there have been few studies focusing on visual displacement 
and velocity perception in relation to PD. The neural and visual processes involved in the 
perception of these modalities will be discussed in the following subsections, along with 
the few observations made for velocity and displacement perception in PD.  
1.5.2.1 The Visual System 
Humans have the ability to recognize a specific object in milliseconds, a mechanism that 
is neurally processed via the ventral visual stream [178]. However, the specific 
mechanisms regarding human object recognition is still largely unknown. Before 
discussing the ventral visual processing stream (which is responsible for processing visual 
representations of objects and object features [179]) a brief outline of the visual system and 
how light information is processed will be presented. When light enters the eye, it is 
focused by the cornea and lenses of the eye onto the retina where the light-sensitive cells 
are located [179, 180]. These retinal cells convert light information to electrical 
information, which is then sent to central neural regions and eventually higher visual 
centres [179, 181]. The information is first transferred through the lateral geniculate 
nucleus (LGN), and from thereto the primary visual cortex (V1) where processing occurs 
[179]. It should be noted that atrophy of the LGN was observed in non-demented PD 
patients suffering from visual hallucinations, indicating potential alterations occurring in 
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the early stages of visual processing for some PD patients [182]. Furthermore, some cells 
of the retina are dopaminergic, with decreased dopamine levels being observed in the fovea 
(most neuronally dense portion of the retina) [183].  
The receptive fields of the V1 neurons organize input from groups of retinal cells 
correlating to a patch of the retina (i.e. retinotopic representation). Each of the V1 cells is 
tuned to a specific, simple visual stimulus (such as a line) from a particular portion of the 
retina.  Neuron groups representing a patch of retina compose a hypercolumn, which are 
organized in a grid structure [179]. These hypercolumns are responsible for extracting 
stereopsis (depth using visual information from both eyes), colour, and line orientation 
information for the specific retinal patch it encodes [179]. Although there are no visible 
pathological changes to the V1 of PD patients, there were observed abnormalities in lipid 
metabolism at the V1 of PD patients [184]. Further primary visual dysfunctions in PD 
include impairments in colour discrimination and contrast sensitivity. 
After information is processed by the V1, it will be sent to the higher visual areas 
where it is continued to be processed. The information is initially sent to the V2 and V3, 
which also display a retinotopic representation. It is in these higher visual areas that the 
simple visual features extracted by the V1 are grouped together into objects. Beyond visual 
feature extraction, an individual’s interpretation of the object plays an important role in 
visual perception (via top-down interpretations), with the higher visual areas being 
responsible for relating images to memories of familiar objects [179]. Beyond the V2 and 
V3, there are many more visual processing centres responsible for the interpretation of 
certain attributes of the image that is being perceived. These higher visual centres are 
mainly part of two streams, the dorsal "where" stream along the intra parietal sulcus 
(involved with perceiving where an object is in space and producing movement to a 
particular location in space), and the ventral "what" stream projecting to the inferior 
temporal lobe (which is responsible for the accurate identification of objects) (Fig. 1.4) 
[179]. The complex processing of visual stimuli allows for simple image features to be 
grouped together and accurately perceived by the individual to achieve detailed vision. 
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1.5.2.2 The Ventral Visual Stream, Object Recognition and 
Parkinson’s Disease 
Current evidence points to the ventral visual stream projecting to the inferior temporal lobe 
as the primary neural component involved in object identification [185]. The neurons of 
this stream encoding certain objects use a sparse strategy, in which there are very few 
neurons coding (and firing upon recognition) very particular objects (such as a known face) 
[185].  The inferotemporal (IT) cortex (comprised of V2 and V3 neurons) is composed of 
neurons which recognize patterns of complex visual features, causing a strong, precise 
neuronal response to specific groups of objects (e.g. neurons that excite to images of a 
specific body part). This information is then sent to the lateral occipital complex (LOC), 
which has specific neuron groups that respond to particular object classes (i.e. horses), or 
specific objects of an object class (e.g. neuron(s) of the fusiform face area which respond 
to a particular individuals face) (Fig. 1.4) [179]. Perceptual learning leads to a "filling in" 
of object features by the LOC, so that familiar objects can be viewed in different 
orientations, or with portions visually occluded and still be accurately perceived [186].  
Through the collecting and compiling of simple visual features of an object, the 
ventral visual stream displays selective neuronal firing (with as few as one neuron) to 
accurately identify an object [185]. In this regard, visual displacement information between 
multiple object features is one of the simple visual features that is neurally extracted and 
utilized in perceiving a certain object. The independent features of the object are patched 
together using cues based on displacements between notable object features measured an 
allocentric manner (using external objects as reference points) as well as feature orientation 
[179]. It should be noted that abnormalities in object recognition as well as specific object 
feature recognition (such as facial emotions) have been observed in PD, although 
attentional deficits and working memory deficits question if these findings signify 
abnormalities in the ventral visual stream [187–191]. In this regard, testing simple 
perceptions that are neurally computed earlier in the ventral visual pathway might aid in 
resolving the confounding observations. The IT cortex is implicated in the perception of 
length and orientation through lesion and fMRI studies [292–294]. To accurately perceive 
displacement, one must perceive both the length and the orientation of the displacement. 
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This provides motivation for the current work which looks to analyze simple linear 
displacements in PD, to observe potential deficits, which might indicate abnormalities in 
the IT cortex of PD patients. 
 
 
Figure 1.4: Visual Processing Pathways of the Brain 
Simple visualization of the dorsal “where” and temporal “what” visual processing 
streams responsible for the processing of visual spatial and visual recognition of objects 
respectively. The primary visual cortex (V1) initially receives information from the retina 
and begins to extract visual features from this light information. This information is 
moved to the V2 and V3 where image processing continues, before continuing on one of 
the two predominant visual processing streams for detailed representation of visual 
stimuli. 
 
 
1.5.3 Visual Spatial perception, Velocity perception and Parkinson’s 
Disease 
In order for an individual to move their body or a limb to a certain location in space, they 
must utilize visual information to accurately perceive their surroundings. The visual 
processing pathway involved visually perceiving space and positioning the body 
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accordingly is the dorsal stream, which follows the intraparietal sulcus (Fig. 1.4) [179]. 
There are several neural regions that are involved in the perception of motion, the primary 
contributor being the area MT+ (containing the MT and MSTl/d areas) situated around the 
ascending limb of the inferior temporal sulcus (ITS). Without the MT+ area moving objects 
would appear as still images transporting through space, making accurate perception of 
velocity very difficult [179, 195]. Unlike the ventral visual stream, the dorsal stream 
neurons have large receptor fields, and visual information is distributed across large 
populations of neurons [185]. Although this means the MT+ has poor visual acuity, it has 
great ability to determine object direction and speed and produces efferent motor signals 
capable of eliciting accurate limb movements [179, 185]. Furthermore, the dorsal and 
ventral visual streams share information, allowing for rapid identification and localization 
of objects [196]. However, the reference point used for measuring the spatial location of 
an object differs from that used in object perception, with spatial processing using one’s 
self as the egocentric reference [197]. These egocentric representations allow us to visually 
map space around ourselves for navigation of the body, which has been shown to be 
abnormal in PD [198, 199]. The LGN cells involved in the dorsal visual stream are sensitive 
to low acuity visual motion in a particular direction, sending this information for further 
processing directly to the MT and indirectly through the V2/3 [179]. 
Similar to the lower visual processing centres, the MT is organized in a grid of 
columns that receive input from a patch of retina. The current model of this neural region 
shows the columns further dividing into mini-columns tuned to a particular direction and 
depth of motion, with each cell of the mini column being tuned to a particular velocity 
[179]. Although this neuronal layout has been proven in monkeys, fMRI work on humans 
has not yet proven that the columnar organization further subdivides to specify motion 
direction [200, 201]. From the MT the visual information is sent to the lateral MSTl or 
dorsal MSTd where it is sued to perceive when an object moves (allowing for object 
pursuit) or when the visual background moves (to sense when the perceiving individual 
moves) respectively [201, 202].  The MSTl utilizes smooth pursuits to persistently remain 
focused on the object being tracked.  Oculomotor impairments in PD cause smooth pursuit 
and saccadic dysfunction, which is improved by dopaminergic medication [119, 203]. This 
could however be due to motor dysfunction as opposed to improper saccade efferent 
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firings. Individuals with PD also display abnormalities in the visual tracking of objects 
[204], which again further provides evidence for impairments in the dorsal visual 
processing stream or instead be caused by motor dysfunction.  Thus, past clinical work has 
shown that processes involving the dorsal visual stream are abnormal in PD, however due 
to movement abnormalities confounding results it is not yet resolved if perceptual 
dysfunction does occur. Evidence for perceptual impairment has been observed in motion 
and orientation perception of moving gradients in PD [128, 205]. These perceptions 
however utilize MSTd information by mimicking the sensation of environmental shift as 
opposed to perceptions involving the movement parameters of an object (processed by the 
MSTl). The accurate perception of object speed is not only important for recreational 
activities, but also for ensuring safety in circumstances using heavy machinery such as 
driving. Findings of driving impairments occurring in PD are potential indicators of dorsal 
stream abnormalities [199, 206, 207], however as this is a complex process involving many 
neural components beyond accurate speed perception of an object further analysis should 
be done to reduce confounding findings. 
1.6 Diagnosis and Monitoring of Parkinson’s Disease 
Though An essay on the shaking palsy by James Parkinson was released in 1817 it was not 
until 1960 that clinical trials began for the use of levodopa in treating PD [208]. Further 
advancements in treating PD symptoms have been made which greatly improve motor 
function, but the outcomes are unreliable for PD non-motor symptoms. Though increased 
knowledge regarding non-motor PD symptoms reveals its significance towards detriments 
in patient quality of life, there are still no therapies aimed at directly alleviating these 
symptoms, and very few clinical evaluations for non-motor symptoms exist. Still, the four 
PD features that are key clinical markers for the diagnosis of PD are resting tremor, rigidity, 
akinesia/bradykinesia and postural instability, even though certain non-motor symptoms 
are recognized as early disease markers [208]. There are numerous PD rating scales that 
provide an evaluation of the motor severity of an individual’s PD. The Hoehn and Yahr 
scale for example provides non-specific assessments of PD progression ranging from a 
score of 0 (non-Parkinsonian) to 5 (immobile unless assisted) [209]. However, the most 
common rating scale used to monitor PD and assess patient impairment is the UPDRS, 
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which is commonly used by clinicians to track disease progression [210].  The UPDRS 
consists of numerous sections; I – Mentation, Behaviour and Mood (assess the presence of 
intellectual and thought impairments, as well as depression); II – Activities of Daily Living 
(analyzes the ability to perform daily activities such as speech, hygiene, walking and 
tremor); III – Motor Examination (examines patient movement ability); IV – complications 
in Therapy (such as dyskinesias and fluctuations), as well as sections relating disease 
severity to modified Hoehn and Yahr staging, and the Schwab and England Activities of 
Daily Living scale (rating out of 100% the patients ability to perform daily activities) [235]. 
Although non-motor symptoms are understood to be significant disease factors 
arising across disease stages, clinical diagnosis primarily uses the cardinal motor symptoms 
of the disease, their response to levodopa, and the exclusion of non-PD motor abnormalities 
[208, 211].  Although the clinical diagnosis of PD is rather straightforward when the 
classical symptoms present early in the disease, many cases arise where current diagnostic 
practices have difficulty (and often fail) with accurate diagnosis [209]. Although 
neuroimaging techniques to assess PD are being explored, there is yet to be enough 
evidence regarding their results to warrant use in clinical applications for the foreseeable 
future [208, 212]. PD diagnosis is currently hindered due to there being vast disease 
phenotypes, while still predominantly focuses on the core motor symptoms, with the 
insufficiencies greatly affecting diagnosis and monitoring of non-motor symptoms. 
Although the UPDRS (the current PD monitoring gold standard) does analyze some non-
motor features of the disease it does not encompass the wide range of symptoms. A non-
motor symptom questionnaire was created to help address these concerns, allowing for 
patients to report their non-motor symptoms which can allow for their monitoring [4].  
Other questionnaires and scales such as the PDQ-39 scale display effectiveness in 
monitoring non-motor symptoms but have little efficacy regarding disease diagnosis [4]. 
Scales such as the Hamilton Depression Score and Epworth Sleepiness Scale are able to 
assess non-motor dysfunction that occur in PD, but are not specific to PD, again limiting 
their effectiveness with disease diagnosis. As the sensory symptoms of PD have been 
shown to appear across disease stages (sometime arising before motor symptoms), it seems 
that they would be rational targets for the diagnosis and monitoring of PD. Unfortunately, 
there are yet to be reliable clinical evaluations of PD sensory symptoms that aid in disease 
30 
 
diagnosis and monitoring [213]. As optimized patient treatment occurs when accurate 
symptom diagnosis and management takes place as early as possible, there are clear needs 
for improved clinical diagnostic techniques to account for the heterogeneous nature of PD. 
1.7 Rationale 
PD presents itself in different manners for different individuals, leading to different 
pathologies and difficulties that the patients must manage. Although the non-motor 
symptoms of PD are not as visible as the motor symptoms, they have been shown to have 
at least as substantial an impact on patient quality of life. However, the breadth of non-
motor symptoms is not fully known, elevating difficulties with diagnosis, monitoring and 
treatment of the disease. This is observed through use of dopaminergic medications and 
DBS therapy to treat PD symptoms, as the marked improvements seen on motor 
functionality are not carried over to the non-motor symptoms that display a much more 
varied therapy response. Perceptual deficits, including those involving visual systems have 
been observed in PD across all stages, often predating motor symptoms. Accurate 
processing of visual information is a fundamental component of countless day to day 
activities and is necessary for the accurate perception of the world around us. Accordingly, 
visual time, speed, and displacement perceptions are used to safely operate machinery, 
navigate space, carry out daily tasks such as driving, and accurately identify objects. 
Abnormalities in processes utilizing these visual modalities suggests perceptual 
impairment, however these deficits could be due to the known sensorimotor integration or 
motor impairments occurring in PD, warranting further analysis. 
Although past decades have seen great increases in known information of non-
motor PD symptoms, there are still no adequate methods of diagnosing and monitoring 
many of the symptoms. However, this should be a priority of disease management as it will 
not only lead to improved treatment, but also could assist in the early diagnosis and 
monitoring of PD as a whole. Since some perceptual symptoms such as olfactory 
disturbances are known often arise before motor symptoms, diagnostic procedures based 
on these perceptual modalities show promise in assisting with PD diagnosis and 
monitoring. As access to technology becomes more wide-spread and cost effective, the 
development of disease monitoring software would come at a time allowing for it to be 
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accessible to vast amounts of individuals, allowing for more convenient, cost effective 
neurological assessment. Considering visual stimuli, designing computer-based diagnostic 
software for these perceptual modalities (should they be affected in PD) would prove a 
much simpler task than diagnostic tools for perceptions such as olfaction, further increasing 
usage potential and accessibility for those in need. Furthermore, due to the heterogeneous 
nature of PD, assessment of the disease from multiple perspectives would lead to 
improvements with its clinical analysis, and thus the patient group as a whole. Based on 
the literature review given above for PD and PD related therapies and clinical assessments, 
as well as the neural basis of visual time, displacement and velocity perception, this thesis 
explores the following hypothesis. 
1.8 Hypothesis 
It is hypothesized that the visual perception of velocity, time, and displacement is abnormal 
in PD patients compared to non-PD individuals, and that the use of levodopa medication 
or DBS therapy for treating PD alters the patients’ perceptual abilities for these tested 
modalities. 
1.9 Objectives 
1.9.1 Objective 1: Are movement-independent visual perceptions 
abnormal in Parkinson’s Disease? 
As discussed throughout this chapter, perceptual abnormalities commonly occur in PD 
across disease stages, however the extent of impairment is not known. We have conducted 
various studies which analyze visual temporal, displacement, and velocity perceptual 
abilities of PD patients. These visual modalities are important contributors to the accurate 
perception of the world visually, and impairments in any would substantially degrade 
patient quality of life and help explain certain phenomena occurring in PD. This work 
aimed to analyze base visual perception abilities independent from any movements that 
could confound results, allowing for the study of visual perceptual ability as opposed to 
motor functioning. Two-alternative forced choice experiments were conducted for visual 
temporal, displacement, and velocity perception. The methodology and outcomes of these 
studies are presented in Chapters 2, 3, and 4 respectively. 
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1.9.2 Objective 2: What is the effect of common PD treatments on 
visual perception ability?  
Previous discussions in this chapter have noted the inconsistent effect of levodopa and DBS 
therapies in the treatment of non-motor PD symptoms, with the current therapies often 
having no beneficial or detrimental effects on these symptoms. To study how popular 
current PD treatments affect the studied perceptions, both levodopa pharmaceuticals and 
DBS were examined in terms of efficacy towards improving visual temporal, displacement, 
and velocity perception. PD patients using these therapies conducted the experiment twice, 
both ON and OFF of their respective treatments. Furthermore, early stage de novo PD 
patients who were not using any PD therapy at the time of testing also conducted the 
experiments, providing insight on how these visual perceptions are affected early in the 
disease progression. 
1.9.3 Objective 3: Development of a computer-generated 
graphical tool for analysis of visual perceptions 
As previously noted, there is a lack of diagnostic methods that address the non-motor 
symptoms of PD disease. Due to the heterogeneous nature of PD and some non-motor 
(including sensory) symptoms presenting before motor symptoms, diagnostic tools 
assessing non-motor PD symptoms would provide valuable clinical tools to assist in the 
accurate diagnosis and monitoring of the disease. In the current work, a computer-
generated graphical tool was designed using the Matlab/Simulink environment to analyze 
and quantify visual perceptions. In this platform, the toolbox was designed to recreate 
specified times visually, as well as use information on the amount of pixels on the testing 
monitor that correlate to certain distances in cm, allowing accurate displacement distances 
and velocities (in terms of the quantity of pixels being displaced and pixels per second 
respectively) to be achieved. Through this, it was possible to display on the computer 
monitor accurate measurements for the specific perceptual, allowing for the design of 
perceptual tests and clinical applications (described in subsequent chapters). Furthermore, 
the ability to present successive stimuli based on experimenter input (for example by 
clicking the left mouse button) was a necessary feature of the tool as it allowed the 
experiments to progress with customized rates, based on the patient’s response rate and 
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desired frequency and duration of break periods. Our goal was to validate the use of the 
graphical tool (or a similar tool) for the assessment of visual perceptions, so that it can be 
successfully used in the assessment of perceptual ability and be further developed into a 
clinical tool for use in assessing visual perceptions.   
 
 
1.10   Thesis Outline 
The chapters are as follows: 
• Chapter 2 assesses the visual temporal perception abilities of PD patients using 
time magnitudes in the range of seconds and milliseconds 
• Chapter 3 assesses the visual allocentric displacement perception abilities of PD 
patients  
• Chapter 4 assesses the visual object velocity perception abilities of PD patients  
• Chapter 5 provides conclusive statements for the thesis, as well as an insight into 
the continuation of the work in the future. 
Each of chapters 2, 3, and 4 analyzes the therapeutic effect of levodopa and DBS on the 
respective perceptual modality and use the computer-generated graphical tool to assess 
perception. 
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Chapter 2  
2 Differential Temporal Perception Abilities in Parkinson’s 
Disease Patients Based on Timing Magnitude 
This chapter contains the text of a paper (with the same title) that is currently being 
considered for journal publication. This work has been published in its preliminary form 
in the 9th International IEEE EMBS Conference on Neural Engineering, San Francisco, 
USA, 2019 conference proceedings, titled “Visual Temporal Perception in Parkinson’s 
Disease Analyzed Using a Computer-Generated Graphical Tool”. 
2.1 Introduction 
Parkinson’s Disease is a progressive neuro-degenerative disease generally characterized 
by neuronal death in the BG, leading to heterogeneous motor abnormalities [1, 2]. Non-
motor symptoms are also present in the vast majority of PD patients throughout all disease 
stages [3, 4]. Although these non-motor symptoms were classically not considered 
substantial factors of PD, they are increasingly being shown to contribute to decreased 
patient quality of life, in many cases to a greater degree than motor-symptoms [3–7]. 
Numerous common PD non-motor symptoms such as olfaction disturbances and rapid eye 
movement sleep behaviour disorder frequently predate the appearance of motor symptoms 
[8, 9]. Accordingly, extensive work has studied the use of non-motor symptoms as early 
disease markers; however, this has not yet lead to reliable methods for the early detection 
of PD [10, 11]. Although non-motor symptoms are known to be both important factors of 
PD and in some cases potential disease markers, accurate diagnosis and treatment of these 
symptoms remains a challenge [12]. Further shortcomings in effective treatment and 
monitoring of non-motor features arise from gaps in knowledge regarding the extent of 
these symptoms. 
Of the studied non-motor deficits occurring in PD, abnormalities in some 
perceptual processes have been observed [4]. One of the perceptual abnormalities that has 
been noted in PD is the disruption of temporal perception and temporal processing [13–
17]. However, like many studies analyzing perceptions in PD, past assessments of timing 
have often required patient movement. As movements are impaired in PD, the timing 
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aspects of these studies are confounded and the main source of the observed deficits is 
unknown [14, 18–20]. It is not clear whether the reported deficits in perceiving the fabric 
of time affecting PD patients arise due to impaired temporal processing, impairments in 
motor timing, or both. The current study sought to address these issues by isolating 
temporal perception from related motor actions allowing for its independent analysis. To 
do this, a novel computer-generated graphical tool was developed and utilized to 
quantitatively assess visual temporal discrimination independent of participation 
movement in patients with PD. As sensory symptoms like olfaction deficits (which arise 
in up to 90% of PD patients) are noted as potential biomarkers for PD [4], there is the 
possibility of other perceptual PD biomarkers. Furthermore, past work has shown abnormal 
neural connectivity occurring during attention-demanding temporal perception tasks is a 
distinguishing factor between PD patients with no clinically significant cognitive 
impairments and control participants [21]. Thus, temporal perception can potentially be 
used in the assessment and tracking of PD. Accordingly, a visual computer-based graphical 
tool was designed to help track and diagnose PD, providing a simple assessment that can 
be used in any setting. 
Further shortcomings of work studying temporal perception in PD are seen in few 
perceptual discrimination (ability to discern between two stimuli differing in magnitude) 
studies in favour of detection (ability to detect stimuli apart from a baseline) tasks, with 
many past discrimination work involving goal-directed movements and one neural timing 
mechanism (i.e. interval timing in the range of seconds) [21, 22]. This is exemplified in 
research conducted by Artieda et al. that concluded those with PD display deficits in both 
motor timing tasks and time estimation tasks across multiple sensory modalities [14, 19]. 
Temporal discrimination is used daily in everyday activities as it is involved in processing 
subjective timing (an individual’s perception of the amount of time that has passed since a 
certain event) [23, 24]. Based on current subjective timing models, different neural regions 
are responsible for timing operations depending on the timing scale [24, 25].  The BG for 
example is believed to be an important component in the perception of time in the range of 
seconds to minutes, while little evidence points to its involvement at the millisecond timing 
range [24]. As PD does not cause dysfunction at all neural regions—but substantial 
abnormalities in some regions such as the BG—it is possible that timing processes of scales 
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utilizing neural regions heavily affected by PD will be affected, whereas other timing scales 
will not be heavily affected in PD. For the reasons discussed above, the computer-generated 
graphical tool was designed to test visual temporal discrimination abilities of PD patients 
in the range of milliseconds and seconds to address these knowledge gaps. 
The primary patient group for the study consisted of mid-stage PD patients using 
levodopa oral medication (half-life: 0.5 - 1.5 hours) to restore neural dopamine levels.  
Levodopa’s reported effect on temporal perception of PD patients has confounding results, 
with some work suggesting levodopa improves internal clock function of PD patients [19], 
and others suggesting its use leads to temporal impairments [26, 27].  Levodopa generally 
produces positive outcomes for the movement abnormalities of PD (such as tremor and 
bradykinesia), however recent MRI work suggests that it also enhances the weakened 
connectivity between the cortico-striatal-thalamo-cortical (CSTC) motor circuit that is 
involved in the control of timing and movement [28, 29]. Dopamine’s influence on timing 
events extends to internal time keeping allowing for accurate and precise time estimations, 
reproductions, and perceptions, as well as direct modulation of CSTC connections involved 
in motor timing [18, 30–32]. Furthermore, the ideal dosage of dopamine for treating PD 
motor symptoms contributes to the "migration effect" occurring in PD, in which small time 
frames are overestimated and large time frames are underestimated [33]. Levodopa in 
general has a variable effect for non-motor PD symptoms, often eliciting no effect or 
detrimental effects [5, 34]. Due to levodopa’s confounding outcomes in past work and the 
inclusion of movements in past PD temporal studies, the effect of levodopa on visual 
temporal perception is still not known. An additional two PD patient groups consisting of 
fewer patients were also tested as case study groups. One of these groups consisted of early-
stage de novo patients (patients who are not yet using any PD therapies [35]). The third 
patient group that was studied had mid- to late-stage PD and exclusively utilized DBS of 
the subthalamic nucleus. The outcome of DBS use is similar to that achieved from levodopa 
use, leading to substantial motor improvement [36]. Also, like levodopa, the non-motor 
effects of DBS therapy are variable and, in many cases, unknown (such is the case with 
temporal perception).  Considering the above, the effect of levodopa and DBS therapy on 
visual temporal perception is still not fully understood, even though this perception is 
critical for interacting in dynamic environments. Patients who were using a PD therapy 
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were studied ON and OFF their respective treatments to analyze their efficacy regarding 
temporal perception. 
The main unit used to quantify an individual’s perceptual abilities was the 
difference threshold (DL; minimum magnitude change needed to differentiate a stimulus 
from a standard stimulus). Two standard stimuli (0.5 seconds and 1 second) were used to 
test temporal perception for timing magnitudes in the range of milliseconds and seconds 
(via interval timing) respectively. These standards were chosen as millisecond and interval 
timing utilize different neural regions and mechanisms [24], we wanted to analyze 
perception of PD patients at both of these timing magnitudes. Furthermore, attentional and 
memory deficits that often affect PD patients would be exacerbated by the testing of greater 
time magnitudes [37–39]). Longer durations would also substantially increase testing 
times, further risking invalid data due to patients experiencing increased fatigue leading to 
attentional slips. 
 In addition to perceptual sensitivity (via DL), this study sought to analyze visual 
temporal perception coherency in PD patients according to Weber’s Law. Work done by 
Weber and Fechner [40, 41] led to Weber’s Law, stating that a person’s difference 
threshold (DL) is directly related to the magnitude of the standard stimulus for a given 
sensory modality. The ratio of DL to a standard stimulus is constant across different 
magnitudes of stimuli, displayed through the Weber’s Fraction (WF; defined as WF = 
DL/S, where S represents the standard stimulus magnitude). The majority of perceptions 
analyzed using WF have validated Weber’s Law, with exceptions seen at extremely low 
stimuli magnitudes [40, 41]. The effect of PD on temporal perception coherency has not 
yet been observed, motivating this study component. Many past works have shown timing 
abnormalities to occur in PD, although several involve motor timing or perceptions linked 
to movements. Furthermore, the BG appears to have a central role in timekeeping (in the 
seconds to minutes range) that is directly modulated by dopamine [24, 42–44]. The BG is 
theorized to increase the frequency of pulsator pulses that are collected and measured to 
determine time durations [30, 32]. Increased dopamine levels in the CSTC circuit also 
reduces uncertainties in time estimations [32]. Alterations in BG activity (due in part to 
dopamine deficiency) appear to cause disruptions in the internal clock’s ’core timer’, motor 
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timing, and decision making involved in time perception [13, 22, 45, 46]. The above 
mentioned notes lead to our primary chapter hypotheses that (A) Visual temporal 
perception (including perceptual coherency) of PD patients is impaired compared to 
control participants, and (B) levodopa will reduce the visual timing disturbances in PD 
patients by restoring BG function, thus tightening the boundaries of temporal function. 
Case studies involving small patient groups were also conducted to see the effect that DBS 
has on temporal perception, as well as to analyze if visual temporal perception is abnormal 
in early-stage de novo PD patients. As DBS improves BG function (acting similarly to 
levodopa), it is also hypothesized that it will provide benefits to a PD patient’s visual 
temporal perception.  Due to the BG still being impaired to some extent in de novo patients, 
it is hypothesized that they will display impairments in visual temporal perception. This 
chapter systematically analyzes visual temporal discrimination at different timescales in 
PD patients independent of goal directed movements that could influence participant 
timing ability, while evaluating the effect of the two common PD therapies and analyzing 
the coherency of the perceptual capability being studied. 
2.2 Results 
2.2.1 Demographic Data and PD-Related Clinical Characteristics 
A total of 37 PD patients were tested: 25 (22 male, 3 female) who use Levodopa, 6 (4 male, 
2 female) who use DBS, and 6 (4 male, 2 female) de novo patients not currently using any 
medication for their PD; as well as 17 control participants (14 female,3 male). All 
participants were residing in the Southern Ontario region at the time of testing. Clinical 
and demographic data related to the PD patients are shown in Table 2.1. Oculomotor 
examination was conducted on all patients by an experienced clinician, and only those 
without deficits were recruited.  
2.2.2 Temporal Perception: Healthy vs. PD 
DL was used to quantify perceptual abilities, with smaller DLs signifying better perceptual 
acuity (and thus ability) (Fig. 2.1). Each participant had two cumulative Gaussian 
distribution functions produced, one for each of the standard stimuli. The slope of the 
function is inversely proportional to DL, with steeper slopes indicating smaller DLs, and 
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thus increased perceptual abilities (Fig. 2.2). The unpaired (independent samples) t-test 
was used to compare DLs of control and PD participants both ON and OFF of levodopa. 
Table 2.1: Demographic and clinical data for PD patients.  
Abbreviations: MoCA - Montreal Cognitive Assessment; UPDRS -Unified Parkinson’s 
Disease Rating Scale 
Demographic Data Levodopa DBS De Novo Control 
Number  25 6 6 17 
Age (years) 70.04 ± 6.80 55.16 ± 8.99 74.17 ± 3.97 67.71 ± 8.82 
Sex (m/f) 22/3 4/2 4/2 3/14 
Years Since Diagnosis 6.88 ± 4.36 11.5 ± 4.04 3.12 ± 2.0 N/A 
Clinical Data 
MoCA (out of 30) 26.68 ± 2.17 26.67 ± 3.08 27.83 ± 2.14 27.23 ± 1.59 
UPDRS motor sub-scale 
OFF Therapy 
23.92 ± 6.69 34 ± 10.51 22.33 ± 7.91 N/A 
UPDRS motor sub-scale 
ON Therapy 
14.72 ± 6.07 22.33 ± 7.91 N/A N/A 
UPDRS motor sub-scale 
OFF vs. ON Difference 
9.20 ± 5.09 21 ± 5.62 N/A N/A 
 
Statistical significance was achieved with values of p ≤ 0.005. A datum point was 
considered an outlier and not considered for statistical evaluation if it was greater than 1.5∗ 
Inter−Quartile Range (IQR) above the third quartile, or less than 1.5 ∗ IQR below the first 
quartile.  
When comparing the DLs for the standard stimulus of 0.5 seconds for all individuals 
with PD (n = 37) to the control subjects, there were no significant differences in temporal 
perception between control subjects (average DL: 0.1867 ± 0.11) and both PD patients 
OFF their respective therapies (average DL: 0.2150 ± 0.076; p-value = 0.280) and ON their 
therapies (average DL: 0.2181 ± 0.086; p-value = 0.259) (Fig.  2.3). However, 
57 
 
 
Figure 2.1: Example Cumulative Gaussian Distribution functions regarding temporal 
perception used for subject analysis. Subject DL was analyzed by subtracting the Point 
of Subjective Equality (PSE) from the Upper Threshold (UT; or subtracting the Lower 
Threshold [LT] from the PSE). UT and LT are the points of the function which the subject 
answered correctly 75% of the time for a given standard stimulus. Larger DLs signify 
decreased perceptual sensitivity. 
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Figure 2.2: Gaussian distributions of temporal perception showing perceptual 
performance of individual participants. Categorized via disease state and standard 
stimulus. Curves are colour coded based on the participants DL (which is inversely 
proportional to function slope) for a certain condition. Curves that are more blue belong to 
participants displaying lower DL’s (greater slopes) and thus having better perceptual 
abilities, with red/orange curves signifying the opposite 
 
when comparing the DLs of control participants for the standard stimulus of 1 second 
(average DL: 0.2233 ± 0.068) to all PD patients, the PD patients OFF their respective 
therapies (average DL: 0.3678 ± 0.130 had significantly greater DLs (p-value < 0.001). 
When PD patients were ON their therapies (average DL: 0.3789 ± 0.14) they also displayed 
significant increases (p-value < 0.001) in DLs for the standard stimulus of 1 second 
compared to control participants (Fig. 2.3). A note on figure 2.3 and subsequent figures 
presented in this thesis, in some cases the y-axis of sub-figures differ from one another. 
The sub-figures with differing y-axis do not have data that is compared to one another, 
instead they contain data from a specific participant group with a certain therapeutic 
condition while providing focus on values of interest. 
As can be seen in Fig. 2.4A), PD participants using levodopa as their PD therapy 
showed insignificant (p-value = 0.434) differences of DLs (average DL: 0.2101 ± 0.083) 
compared to control participants (average DL: 0.1867) when OFF levodopa at the standard 
stimulus of 0.5 seconds. When ON levodopa, PD participants again showed insignificantly 
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(p-value = 0.345) differing DLs (average DL: 0.2176 ± 0.098) compared to control 
participants at the standard stimulus of 0.5 seconds (Fig. 2.4A). For the standard stimulus 
of 1 second, PD participants OFF levodopa displayed significantly greater (p-value = 
0.003)  
 
Figure 2.3: Temporal perception difference thresholds of all PD patients (n = 37) 
regardless of treatment state compared to control participants. The standard stimulus 
of 0.5 seconds is displayed on the left, and 1 second on the right; with boxplots related to 
PD patients OFF and ON their respective therapies. The red lines are the median DL for 
each group. The bars represent the data spectrum. PD patients did not show any 
impairments in temporal perception at the standard stimulus of 0.5 seconds ON or OFF of 
PD therapies. However, there were significant impairments seen at the standard stimulus 
of 1 second OFF PD therapies (p-value <0.001) and ON PD therapies (p-value < 0.001). 
 
 DL’s (average DL: 0.3351 ± 0.024) compared to the control participants (average DL: 
0.2233). Again, when using levodopa, similar results were seen, with PD participants ON 
levodopa displaying significantly greater (p-value < 0.001) DL’s (average DL: 0.3806 ± 
0.14) compared to the control participants (Fig. 2.4B). 
 It should be noted that both the DBS and de novo PD groups have relatively small 
n-values (n = 6 each). Thus, the statistical evaluation that was conducted on these groups 
should serve as observations of interest for these particular groups. The statistics do not 
necessarily represent these patient populations, however the trends seen do provide insight 
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to the temporal perception abilities of these groups, providing interesting case studies and 
rationale to further expand testing to support larger patient groups. Participants with PD 
who were utilizing DBS therapy in general displayed similar results to PD participants 
using levodopa.  At the standard stimulus of 0.5 second PD participants OFF DBS 
 
Figure 2.4: The difference thresholds separated by individual therapies obtained 
through temporal perception examination The standard stimulus of 0.5 seconds is 
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displayed on the left, and that of 1 second on the right. The redlines are the median DL for 
each group. The bars represent the data spectrum. Regarding the standard stimulus of 0.5 
seconds, there were no significant differences in DLs observed between PD patients OFF 
and ON levodopa and DBS compared to controls. De Novo PD patients did not display 
significant differences in DL compared to controls as well. Use of levodopa and DBS 
therapies did not lead to significant changes in the DLs of PD patients. For the standard 
stimulus of 1 second, significant differences in DL were observed between PD patients 
OFF and controls (p-value = 0.003), as well when ON levodopa and controls (p-value < 
0.001) were also seen. PD patients using DBS displayed significant increases in DL when 
OFF DBS (p-value < 0.001), however when ON DBS no significant DL increases were 
seen when compared to controls. De Novo PD patients also displayed significantly greater 
DLs than controls (p-value = 0.002) at the standard stimulus of 1 second. No significant 
differences were seen when PD patients were administered their respective therapies at the 
larger standard stimulus of 1 second. 
 
displayed insignificant (p-value = 0.276) DL differences (average DL: 0.2460 ± 0.076) 
compared to control participants (average DL: 0.1867). When ON DBS, the PD 
participants also displayed insignificant (p-value = 0.393) DL differences (average DL: 
0.2290 ± 0.071) at the 0.5 second standard stimulus compared to controls (average DL: 
0.1867) (Fig. 2.4C). Like participants using levodopa, at the larger tested standard stimulus 
magnitude (of 1 second) PD participants OFF DBS displayed significantly greater (p-value 
< 0.001) DLs (average DL: 0.5062 ± 0.14) compared to the control participants (average 
DL: 0.2233). However, when ON DBS, no significant differences (p-value = 0.018) were 
seen between the means of PD participants ON DBS (average DL: 0.3873 ± 0.22) 
compared to controls (average DL: 0.2233) at the larger temporal magnitudes of 1 second 
(Fig. 2.4D). 
The third PD group that was tested consisted of de novo PD patients who were not 
undergoing any treatment for their PD at the time of testing. At the smaller tested standard 
stimulus of 0.5 seconds, the de novo PD patients showed did not significantly differ (p-
value = 0.633) in mean DL (average DL: 0.2093 ± 0.043) compared to control participants 
(average DL = 0.1867) (Fig. 2.4E). However, as with all other PD patient groups there was 
significant increases (p-value = 0.002) seen in the DLs of de novo PD patients (average 
DL = 0.35565 ± 0.021) compared to control participants (average DL: 0.2233) (Fig. 2.4F). 
62 
 
2.2.3 Effect of Levodopa and Deep Brain Stimulation on Temporal 
Perception 
To analyze the effect that levodopa and DBS has on the temporal perception of PD 
participants, the paired two-tailed T-test was used, with statistical significance being 
achieved with p-values ≤ 0.05. The use of levodopa did not elicit any significant effects on 
temporal perception for the PD participants using the therapy. At the smaller tested 
magnitudes of time using the standard stimulus of 0.5 seconds the use of levodopa did not 
significantly alter patient DL compared to when the participants were OFF levodopa (p-
value = 0.707) (Fig. 2.4A). At the greater tested magnitudes (using a standard stimulus of 
1 second) there were no significant differences (p-value = 0.074) seen when levodopa was 
used, however a potential trend may be present regarding the increase of participant DL 
when ON levodopa compared to when OFF (Fig. 8B). Similar to levodopa, the use of DBS 
therapy did not elicit significant changes in patient temporal perception. With regard to the 
smaller standard stimulus (0.5seconds), the use of DBS did not lead to significant 
alterations between participants DLs (p-value = 0.257) (Fig. 2.4C). At the standard 
stimulus of 1 second there were no significant differences (p-value = 0.123) in DL when 
DBS was turned ON vs. OFF, however again a potential trend regarding the effect of DBS 
may be present regarding DL improvement when the patients DBS device was turned ON 
(Fig. 2.4D). A note of interest, when comparing a participants DL (considering all 
participants with PD) OFF their respective therapies to the UPDRS subsection III scores 
there were significant correlations at both the standard of 0.5 seconds (R = 0.570; p-value 
< 0.001) and the 1 second standard (R = 0.339; p-value = 0.050). When PD patients were 
using their respective therapy however, there were no significant correlations between an 
individual’s DL and UPDRS section III score for both the 0.5 second standard (R = - 0.131; 
p = 0.483) and the 1 second standard (R = 0.085; p-value  = 0.655). 
2.2.4 Temporal Perception Coherency 
To analyze the perceptual coherency of participants, the WF was calculated at both 
standard stimuli magnitudes. In normal, healthy conditions, it is expected that there will be 
strong correlations between the WFs for the different standard stimuli (as an individual’s 
WF is constant across standard stimuli magnitudes). To analyze this in study participants, 
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Pearson correlation coefficients were applied to compare the similarity between WFs at the 
two tested standard stimuli. Note that in perfectly idealized conditions the slope of the line 
of best fit used in calculating the Pearson correlation coefficient (R) will be 1 (as the WF 
of both the y- and x-axis’ are the same), will have an axis intercept at (0,0), and R will 
equal 1. Deviations in the slope and the y-intercept of the line of best fit will lead to 
decreases in R, signifying abnormal relationships between WF of different standard stimuli 
and thus abnormal perceptual abilities across participant groups. Statistical significance 
was achieved with values of p ≤ 0.05. For the control group there were very strong WF 
correlations between the two tested standard stimuli (R: 0.932, p-value < 0.001).  Although 
not as 
 
Figure 2.5: Correlations between participant WF at the standard stimuli of 0.5 and 1 
seconds. Points displaying high similarity between their x and y values signify that the 
participant displayed little to no difference in the WF values at different stimulus 
magnitudes, and thus are in accordance with Weber’s Law. Correlation plots of DBS and 
de novo patients are not shown due to small sample sizes (n = 6 for each group). 
 
strong of a correlation was seen in all PD patients OFF their respective therapies, they still 
displayed significant, strong correlations between the WF at different standard stimuli 
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magnitudes (R: 0.648, p-value < 0.001). When all PD patients ON their respective therapies 
were analyzed, significant correlations were also seen between WFs (R: 0.362, p-value = 
0.045), however the correlation was not as strong as when OFF PD therapy. When looking 
at PD patient groups separated by PD therapy usage, PD participants OFF levodopa also 
showed strong WF correlations between the two tested standard stimuli (R: 0.612, p-value 
= 0.001). However, when these PD patients were ON levodopa they did not display 
significant correlations between their WFs at the two tested standard stimuli (R: 0.325; p-
value = 0.112). For PD participants using DBS, no significant correlations for the WFs 
between standard stimuli were observed in OFF (R: 0.635, p-value = 0.176) and ON (R: 
0.608, p-value = 0.200) DBS states. De novo PD patients did not show any significant 
correlations between the WFs of the two standard stimuli (R: 0.691, p-value = 0.129) as 
well (Fig. 2.5). 
2.3 Discussion 
The current work showed overall that individuals with PD displayed impairments in the 
tested visual temporal discrimination task (regardless of disease duration) compared to 
healthy controls. In addition, levodopa and DBS therapies were shown to elicit minimal 
effect on the temporal discrimination, and, perceptual coherency was generally disrupted 
in PD patients. It should be noted that the average age of DBS patients was significantly 
lower than that of the levodopa, de novo and control participant groups. The effect of age 
did not appear to affect a participants DL as no correlations were seen between a 
participants age and DL. Furthermore, the duration of PD for DBS patients on average was 
significantly greater than the Levodopa and control participant groups, which is assumed 
due to them being at late stages of the disease. Interestingly, both OFF and ON therapy for 
both the 0.5 and 1 second standard stimuli significant correlations between a patient’s years 
since PD diagnosis and DL were seen. It should be noted, the statistical findings for the 
DBS and de novo groups should not be considered conclusive evidence for the temporal 
perception findings in these groups due to their small sample sizes. Instead, these case 
studies provide an interesting view on how patients at different disease stages and utilizing 
different treatments are affected with regards to temporal perception ability. The main 
findings of this study are in-line with past work showing impairments in time perception 
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and processing for PD patients, as well as work signifying the BG’s importance in temporal 
perception at specific time magnitudes [14–17, 19, 20, 48].  The current study however has 
observed these impairments independent of task-related patient movement, as well as 
differential perceptual ability based on the scale of time that was used during testing. It 
should be noted that these impairments are not attributed to abnormalities in oculomotor 
control, deficits in visual acuity, or clinically diagnosed cognitive deficits common in PD 
(such as Parkinson’s Disease Dementia [PD-D] or Parkinson’s Disease related Visual 
Hallucinations [PD-VH]) as participants were tested diagnostically for these symptoms. 
Furthermore, it is unlikely that the observed deficiencies seen in PD subjects were due to 
deficits of attention or working memory which commonly affect persons suffering from 
PD [49], as there was no deficit seen in the perception of time at the smaller tested 
magnitudes. Thus, the observed temporal perception impairments are likely due to 
abnormal timing processes occurring in PD. 
Subjective timing processes for different time scales achieve different goals and are 
controlled by different neural regions [23, 24]. In this regard, timing in the range of 
milliseconds is responsible for proper motor control, speech recognition and production, 
and playing music [50–52].  The cerebellum has been shown to be the primary neural 
structure involved in millisecond timing through cerebellar lesion studies of motor timing 
and rapid, discontinuous timing tasks, with neuroimaging studies providing further 
evidence [53–56].  Furthermore, based on current research, there is no conclusive evidence 
that the BG are involved in neural timing in the range of milliseconds [57]. The current 
work observed no vision-based temporal perception impairments at the smaller tested 
standard stimulus (utilizing time scales only in the millisecond range) in PD participants, 
coinciding with current knowledge regarding subjective timing in the range of 
milliseconds. Although connections between the cerebellum and BG exist [58], there has 
been no evidence suggesting the BG’s involvement in millisecond timing, which is further 
confirmed by the results in the current study. Timing in the range of milliseconds is 
however important for the control of motor functions and motor timing, which are known 
to be impaired in PD [20, 23, 24, 59]. These motor timing impairments seen in previous 
studies can be attributed to abnormal motor function occurring in PD, as suggested by the 
current study and past work comparing motor timing in PD patients and people with 
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cerebellar lesions [60]. Interestingly, it was previously shown that millisecond timing was 
heterogeneously impaired in some (but not all) PD patients [61], however as all tasks 
involved motor timing these observed abnormalities likely indicate heterogeneous motor 
timing in the millisecond range for PD patients. The PD patients tested in the current study 
did show correlations between perceptual impairment and disease duration for both the 0.5 
and 1 second standards. This could indicate that at earlier stages of the disease when the 
BG is the predominantly affected neural region that timing processes utilizing the BG are 
impaired.  As the disease progresses and spreads to other neural regions impairments in 
timing processes that don’t involve the BG might occur (such as millisecond timing). 
However, this could also be caused by a general increase in impairment (perceptual or 
otherwise) occurring as PD progresses. The core findings of the current study appear to 
confirm that timing processes in the scale of milliseconds independent of motor functions 
are not impaired in PD, providing further evidence that the timing control elicited by the 
cerebellum at this scale functions independently of the BG. 
Timing processes in the range of seconds to minutes utilize the interval timing 
method, which is believed to involve attention of current events and memories of past 
events to estimate time duration [24].  Interval timing utilizes multiple neural regions 
including the BG, with the SNc (dopamine producing cells of BG that experience mass 
neuronal loss during PD) modulating timing processes of the Striatum [24, 48, 62]. With 
this considered, past findings of abnormal temporal production, reproduction, and 
estimation in PD patients aligns with the postulated interval timing models largely 
involving the BG [14, 19, 20, 59, 63]. At the larger tested magnitudes (standard stimulus 
of 1s), patients utilizing levodopa (when both ON and OFF), as well as de novo patients, 
and DBS patients OFF stimulation displayed significant impairments in temporal 
perception compared to control participants, with potential trends regarding impaired 
temporal perception for DBS patients ON therapy also being observed.  These findings 
demonstrate that visual temporal discrimination independent of movement is indeed 
abnormal in PD, yet there are limitations on these abnormalities based on the BG’s role as 
an internal clock.  Interestingly, observations demonstrating a discrepancy in temporal 
perception occurring in PD based on the scale of time was seen. This work strengthens 
postulated subjective timing models in the range of milliseconds–controlled by the 
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cerebellum with no (or negligible) BG influence–and interval timing models which are 
largely influenced by the BG. Interestingly, past work investigating weakened CSTC 
circuit activity in PD that is at least partially responsible for timing deficits suggest 
increased cerebellar activity occurs to attempt to compensate, potentially indicating 
entirely different timing processes occur during PD [29]. The current study has also 
demonstrated that these perceptual abnormalities are occurring early in disease 
development. As previously studied perceptual deficits occurring in PD such as olfaction 
often predate disease motor symptoms [4], it is possible that visual temporal abnormalities 
also predate motor symptoms, providing an easy to test disease marker. 
The use of the two tested therapies did not elicit any significant effects on the visual 
perception of time.  At the lower temporal magnitudes (standard stimulus of 0.5 second) 
this is expected as the postulated timing mechanism is controlled by the cerebellum, which 
is not dopamine dependent [23, 24, 27]. The lack of effect caused by levodopa at the larger 
tested magnitudes (standard stimulus of 1 second) is more peculiar due to the postulated 
role of BG in time perception at this scale and the occurrence of reduced striatal dopamine 
levels in PD [23, 24]. Although studies have attributed levodopa to improved internal clock 
function [64], this could be attributed to improvements in working memory (an important 
component of interval timing) caused by levodopa. As the time scales were rather small in 
magnitude for the current study, this may have reduced error’s that occur from abnormal 
working memory and memory systems rooted in improper striatal activation, which are 
aided by dopaminergic therapy [22]. Furthermore, the detrimental effect of dopamine 
antagonists on internal timing seems to be more pronounced than beneficial effects of 
dopamine agonists [65–67]. Interestingly, if any trend is occurring from levodopa use it is 
negative, which has also been observed in previous work [27]. However, based on the 
statistical analysis, levodopa did not lead to significant alteration in PD patient’s 
capabilities in the tested visual perception task. The use of DBS did not lead to significant 
alterations in a subject’s ability to perform the perceptual task either. However, there was 
a potential trend towards DBS-based improvements in the perceptual task. Due to the small 
sample size, it is possible that the statistical analysis is not representative of the effect of 
DBS on temporal perception, yet, previous work showed neural timing improvements after 
DBS of the subthalamic nucleus [25]. Based on the finding of the current work, it appears 
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that DBS may be more effective at restoring temporal perceptions in the absence of motor 
actions, however both PD therapies have minimal if any effect on the tested visual temporal 
perception. The finding that correlations exist between and individuals UPDRS part III 
subsection score and DL OFF the patient’s respective therapy suggest that like motor 
abnormalities of PD, sensory abnormalities (or in the least the tested visual temporal 
perception) also further deteriorate as the disease progresses. However, the lack of 
correlations when patients were ON their therapies between a subject’s UPDRS part III 
score and DL further suggests that while the tested PD therapies do improve movement 
abnormalities of PD, they do not have the same positive outcome with visual temporal 
perception. Although Weber’s Law is maintained for the majority of tested sensory 
modalities, past work has questioned its merit in temporal perception [68].  Linear 
relationships between perceptual accuracy and stimulus magnitude (via Weber’s Law) 
intemporal perception were shown to occur in healthy subjects between 0.2 – 2 seconds; 
however, other work involving visual timing showed consistency in the WF of standard 
stimuli at 0.6 and 0.9 seconds, but not at 1.2 seconds [68]. In the current work, strong 
correlations between WFs from the two tested standard stimuli were seen for control 
participants and PD participants OFF therapy (as well as PD patients using levodopa when 
OFF medication). Interestingly, no significant correlations between WF calculations at 
different standard stimuli were seen when these patients were ON levodopa. Although 
perception coherency via Weber’s Law did occur in the tested healthy patients, it is still 
not certain whether Weber’s Law is maintained in visual temporal perception across a wide 
range of stimuli magnitudes.  However, this finding further promotes the possibility of 
levodopa acting negatively in terms of visual temporal perception, prompting further 
research into both levodopa’s effect on temporal perception and Weber’s Law in relation 
to this perception. No correlations in WFs between the 0.5 and 1 second standards were 
seen in patients using DBS therapy (both ON and OFF) and de-novo patients. This is likely 
partially due to the small sample sizes of each group (n= 6 for both groups).  
The small sample sizes of both the DBS and de novo groups were a limitation of 
the current work. Due to restricted patient recruitment/testing time frames, as well as a 
small candidate pool for the DBS group (with only 10% of potential candidates utilizing 
the treatment) and de novo group (due to the recruitment centre [University Hospital] being 
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a tertiary care hospital) the recruitment of large numbers of PD patients in these groups 
was a challenge.  However, the results from these groups provide interesting insight into 
how these populations might function with regards to temporal perception, prompting 
further research of the groups. Further study limitations were the constant order of patients 
conducting experiments first OFF PD therapies, followed by ON therapies. This was due 
to the testing occurring in one day, and the approximate 12 hours needed for an individual 
to be considered clinically OFF levodopa (which all non-de novo PD patients were utilizing 
for treatment). Although this is common practice for PD experiments involved ON/OFF 
analysis, and extended breaks were provided for participants, fatigue could have occurred 
for some participants. 
The current study demonstrated abnormalities in visual temporal discrimination 
independent of goal-directed movement occur in PD in timing scales utilizing interval 
timing. However, these deficits were not seen with millisecond timing. This supports 
commonly postulated subjective timing models outlining the BG’s lack of function in 
neural timing in the millisecond range, and involvement in neural timing in second to 
minute range.  This was also seen in early stage de novo PD patients, suggesting that visual 
temporal discrimination is disrupted early in the disease. Thus, visual temporal 
discrimination shows potential as an early disease marker that could be used in diagnostic 
scenarios, due to the simplicity of testing this perception. A non-invasive, easy-to-use 
computer graphics-generated tool was implemented to test this perception. The toolbox can 
be easily modified, allowing for the analysis of different sensory modalities in research or 
clinical settings.  Furthermore, the toolbox is not taxing from a computer processing 
standpoint, allowing it to be used in a wide variety of clinical and non-clinical settings. 
Testing of early stage PD patients (specifically those who do not yet display significant 
motor impairments) should be carried out to further analyze a potential diagnostic use of 
the toolbox for neurological disorders such as PD. As non-motor PD symptoms often arise 
before motor symptoms [4], this tool or similar software could be a valuable asset to assist 
physicians with early diagnosis of the disease. Furthermore, potential clinical importance 
of the computer-generated graphical tool is exemplified through its design, as no goal 
directed movements which could confound perceptual analysis occur, contrasting current 
diagnostic timing tests (such as the Purdue peg board) which utilize extensive movements 
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[69]. Although movements (via talking) were necessary for the analysis, these actions had 
zero impact on the analyzed perception as response time was not a considered factor, 
ensuring motor capabilities had no role in the observations. Due to the simple to use, 
flexible nature of the graphical tool, its use could assist in the widespread monitoring of 
neurological disorders, potentially in the comfort of the user’s home or local community 
centres should it be further validated. This could allow for more regular disease monitoring 
that benefits from the tool’s accessibility, further assisting disease prognosis by providing 
more complete disease analytics for clinicians to utilize. Further studies should also 
investigate a potential use of the toolbox for predicting the onset of PD-D (which may have 
visual markers such as abnormal colour perception [70]) to further assist physicians with 
the monitoring of the disease.  Many current PD monitoring tools focus on motor symptoms 
of the disease [71, 72]; however, disease phenotype varies from patient to patient, meaning 
many do not receive optimum treatment for their conditions or realize the extent of their 
disease symptoms. The graphics-tool used in this study provides a simple means for 
analysis of non-motor perceptual modalities affected in neurological disorders such as PD. 
Future work will continue testing visual perceptual modalities in PD, as well as assess 
perceptual abilities at different disease stages and for different sensory systems (such as 
auditory perceptions) to further validate the use of perceptual testing toolboxes in clinical 
and research use. We hope that the computer-generated graphical tool will one day be used 
in conjunction with other state of the art clinical diagnostic/disease monitoring tools to 
provide improved clinical outcomes for the treatment of neurological disorder, allowing 
those suffering to have the greatest quality of life that is possible. 
2.4 Methods 
2.4.1 Demographics and Clinical Assessment 
The study protocol for this work was approved by the Research Ethics Board of the 
University of Western Ontario.  All experiments were conducted in accordance with the 
Declaration of Helsinki, as well as the Tri-Councel Policy Statement of Ethical Conduct 
for Research Involving Humans in Canada.  All participants provided informed consent 
regarding their participation in the study. Furthermore, the participant displayed in Fig. 2.6 
provided consent allowing for their image to be used in publications of the research. All 
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participants in the study were recruited from the Movement Disorders Program at 
University Hospital, London Health Sciences Centre, Ontario, Canada, where they were 
diagnosed and have been regularly treated for their PD. Study protocol details and consent 
forms were provided to patients prior to participation. For this study, 25 participants were 
recruited who had mid-stage PD (22 male, 3 female) and were on levodopa therapy. Six 
patients with mid-late stage PD were recruited who have been receiving DBS therapy (4 
male, 2 female), as well as 6 early-stage PD de novo patients who were not currently 
receiving any treatment for their PD. Table 2.1 provides the clinical details and 
demographic data about the recruited participants. In addition, 17 healthy, age-matched 
control participants (14 female, 3 male) with no known neurological or psychiatric 
disorders were recruited for the study. The patients and participants were from the Southern 
Ontario region of Canada. For this study, all PD patients fulfilled the UK Parkinson’s 
Disease Society Brain Bank Diagnostic Criteria. Participants utilizing levodopa therapy 
refrained from taking the medication 12 hours prior to experimentation, ensuring that they 
were in the OFF levodopa state. Similarly, participants receiving DBS had their device 
turned OFF upon arrival at the testing centre. These participants had to wait at least 45 
minutes, ensuring that they were not experiencing any effects from the DBS therapy. After 
the participants completed the experiment in the OFF state, they were administered 300 
mg of levodopa if this was their primary therapy (unless their regular levodopa dose was 
100 mg or less, in which case they were administered 200 mg); or their DBS device was 
turned ON to the patients regular stimulation levels if their primary PD treatment was DBS. 
After an hour’s break the participants went through the experiments again in their ON state. 
All participants conducted the experiment ON and OFF PD therapy in a one-day testing 
session. It should be noted that although participants utilizing DBS typically would take it 
alongside levodopa, for the duration of the experiment they did not take any levodopa 
medication. This was to ensure that the effect of DBS was not confounded by the effect of 
levodopa. The severity of motor symptoms affecting the PD participants was assessed 
using the motor subsection (section 3) of the UPDRS both ON and OFF PD therapy. All 
PD subjects also conducted a cognitive assessment using the Montreal Cognitive 
Assessment (MoCA) [73]. Assessments of visual acuity (reading tasks and tests using the 
Snellen eye chart), smooth pursuit and saccades were carried out for all participants 
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(including control participants). Furthermore, the control group was questioned to detect 
symptoms of neurological disorder (including PD) as part of the control participant 
screening. Exclusion criteria (for both control and PD groups) include the presence of 
considerable cognitive impairments (MoCA < 25), impairments in visual diagnostic tasks, 
and the presence of visual hallucination (VH). Furthermore, PD patients utilizing 
pharmacological therapies other than Levodopa were excluded from the study.  
 
 
Figure 2.6: Experimental Setup and Visual Temporal Perception Task 
For testing the LG Flatron W2242PM 22-inch (resolution 1680 x 1050) computer monitor 
was used, with participants sitting at a comfortable viewing position approximately 2 feet 
away from the monitor. The testing room has only the participant and experimenter, with 
excess stimuli (such as sounds, distracting visual) minimized. Illustrative examples of the 
visual temporal discrimination task shown on right, with each quadrant section 
representing a specific time window in a single trial on the computer monitor viewed by 
the participant. In each trial, the participant compares the time period between the 
appearance of circles to the time period between the appearance of circles. The participant 
verbally answers which time period they perceived to be smaller. The example trial begins 
with Image 1 being shown for 1 second, followed by Image 2 being shown for 0.5 seconds, 
followed by Image 3 being shown for 1 second. After a 1 second period where the screen 
is blank, Image 4 is shown for 1 second, followed by Image 5 being shown for 0.7 seconds, 
followed by Image 6 being shown for 1 second 
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2.4.2 Testing Apparatus 
A graphics-enabled tool running in Matlab/Simulink was designed at Canadian Surgical 
Technologies and Advanced Robotics (CSTAR) to examine vision-based temporal 
perception. The graphical environment of this toolbox can be easily modified, allowing for 
the examination of various visual sensory modalities. The tool was utilized to study visual 
temporal discrimination in the current study, with all visual inputs being displayed on an 
LG Flatron W2242PM 22-inch monitor (resolution: 1680 x1050). The participants sat 
approximately 2 feet away from the monitor (Fig. 2.6). The height of the chair and the 
monitor were adjusted for optimum comfort. In order to reduce possible visual and auditory 
distractions, the subjects were located in an isolated room with the experimenter. Fig. 2.1 
shows the station utilized for the experiment. 
2.4.3 Experiment 
A two-forced alternative choice experiment consisting of 160 trials based on the method 
of constant stimuli for difference thresholds described by Gescheider [40] was carried out 
to examine temporal perception. Each trial in the experiment began with a large, central 
white circle appearing in the middle of the computer monitor for 1 second before 
disappearing, leaving a blank screen. After a variable amount of time, the white circle 
reappears for 1 second, before again disappearing. This is followed by the appearance of a 
large, central white triangle on the monitor for 1 second, disappearing for a variable amount 
of time, and reappearing for 1 second before disappearing. At the end of each trial the 
subject compares the period of time between the appearance of the circles to the period of 
time between the appearance of the triangles, verbally answering which time period they 
perceive to be the shortest (can alternatively be thought of as "which shape was blinking 
the fastest"). The participant had no time constraints regarding their response, thus although 
movement was necessary to produce a response, it had no effect on the analysis of patient 
perception. At the 80th trial, a mandatory break was given to the participants, with as many 
additional breaks as desired by the participants given throughout the experiment. Two 
standard stimuli of 0.5 and 1 seconds were tested, with one of these two standard stimuli 
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being present in every trial. The presentation of stimuli comparisons was completely 
random, with both standard stimuli being blended together for testing. For each standard 
stimulus there were 8 comparison values: 0.1, 0.3, 0.4, 0.45, 0.55, 0.6, 0.7 and 0.9 seconds 
for the standard stimulus of 0.5 seconds; and 0.2, 0.6, 0.8, 0.9, 1.1,1.2, 1.4 and 1.8 seconds 
for the standard stimulus of 1 second. The comparison values were chosen so that those 
differing in magnitude the least from the standard stimulus was answered correctly 
approximately 50% of the time, and those differing the most in magnitude from the 
standard stimulus were almost always answered correctly (Fig. 2.6). It should be noted that 
control and de novo PD patients conducted the experimental task once, whereas the PD 
patients using levodopa and DBS conducted the task twice (in both their ON and OFF 
states). It is unlikely that the repetition of the experiment lead to improvements based on 
experiment familiarity however as the PD participants only conducted the task once in a 
given therapeutic state (with task familiarity not transferring over through therapeutic 
states). Furthermore, although the enhancement of neural networks related to visual 
perceptual tasks can occur in adults (i.e. visual perceptual learning), this is a long-term 
change that would not occur in a single experimental session (such as our work) [74, 75]. 
2.4.4 Analysis 
The number of correct and incorrect responses were computed for each comparison value 
of a particular standard stimulus. These values were input into the Psignifit 4.0 third party 
Matlab toolbox, creating a cumulative Gaussian distribution psychometricfunction76. 
From the psychometric function the Point of Subjective Equality (PSE), Upper Threshold 
(UT) and Lower Threshold (LT) (points on cumulative Gaussian distribution function 
correlating to 0.5, 0.75 and 0.25 points on the x-axis respectively [Fig. 2.1]) were obtained 
and utilized to calculate the participants difference threshold (DL), calculated as DL = PSE 
− LT or DL = UT − DL (Fig. 2.1). As described by Gescheider [40], the DL is a value that 
signifies the difference in the stimulus magnitude necessary for a participant to discern a 
stimulus as being different from the standard stimulus that it is compared to. Thus, the 
smaller one’s DL is the more sensitive they are towards the tested perceptual modality at 
the given standard stimulus [40]. Apart from perceptual sensitivity, the perceptual 
coherency of a participant was also analyzed using WF. According to Weber’s Law, the 
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ratio of DL to standard stimulus is constant across the magnitudes of stimuli [40]. This is 
displayed through the WF, defined as WF=DL/S, where S represents the standard stimulus 
magnitude.  
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Chapter 3  
3 Abnormal Vision-Based Displacement Perception and 
Perceptual Linearity in Parkinson’s Disease 
This chapter contains the paper (with the same title) that is being considered for journal 
publication. This work has been published in its preliminary form in the 40th 
International Conference of the IEEE Engineering in Medicine and Biology Society, 
Honolulu, USA, 2018 conference proceedings, titled “Visual Displacement Perception in 
Parkinson’s Disease Analyzed Using a Computer-Generated Graphical Tool”.  
3.1 Introduction 
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the 
degeneration of dopaminergic neurons in the brain stem [1]. The disease phenotype is 
typically classified by the heterogeneous presence of motor symptoms such as resting 
tremors and muscle stiffness [2]. However, non-motor symptoms can arise at all disease 
stages, often posing greater detriments in patient quality of life, and eliciting greater 
influence on institutionalization and economical health burdens compared to motor 
symptoms [3–5]. The current PD monitoring practice lacks accurate diagnosis of non-
motor impairments, thereby leading to a lack of recognition and treatment for many of 
these symptoms [3, 6]. Furthermore, the severity and extent of non-motor impairments has 
not been fully described in PD [7]. The breadth of knowledge regarding non-motor PD 
symptoms is however growing, with an increasing amount of research on sensory, 
neuropsychiatric, autonomic, and sleep dysfunction [8].  
In this regard, visual and oculomotor dysfunctions have frequently been observed 
in patients suffering from PD [3, 9, 10]. Impairments in colour contrast perception, 
hallucinations, and oculomotor control were some of the first documented visual 
impairments in PD, arising across many disease stages [11–14]. Visuospatial abnormalities 
also commonly affect individuals who have PD, with 78% of patients in a self-reporting 
study displaying either visual, visuospatial or both visual and visuospatial deficits [15].  
Although these spatial deficits can hinder performance in memory, representation and 
perceptual tasks in three-dimensional space, they can also pose risks to the patients’ health 
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and quality of life [15]. Visuospatial impairments contribute to balance deficits, increasing 
the chance of falling, thus, increasing the risk of injury; which can be exceedingly 
problematic as PD patients display greater reliance on vision for movement than their non-
PD counterparts [15–17]. Abnormal visuospatial perception of objects in the environment 
also contributes to movement abnormalities in PD such as freezing of gait (FOG; difficulty 
with the initiation of walking) [18, 19]. Furthermore, impairments in attentional tasks and 
tasks involving accurate limb movement in response to perceived visual stimuli occur in 
PD [20, 21]. However, most of the studies that have explored visual perceptions caused by 
PD have involved associated movement responses, raising the question: what is causing 
the observe dysfunctions? Sensorimotor integration impairments are well documented in 
PD, and likely contribute to many of the studied visual perception deficits [22–24]. In 
addition, the BG - a brain region drastically affected by PD - is known to be an important 
group of subcortical nuclei involved in the production and fine tuning of accurate 
movements [25]. Thus, it is not clear in many studies if there are abnormalities in isolated 
visual perceptions of space, or if the deficits are caused by sensorimotor integration and/or 
motor deficits arising from movements produced in response to the tested visual stimuli.  
Although those with PD show deficits in proprioceptive displacement and 
egocentric (visual perception using one’s own body as a reference point) displacement 
perceptions [23, 26–29], allocentric (visual perceptions using an object as a reference 
point) displacement perception independent of motor outputs has not been investigated yet. 
Neural regions associated with allocentric visual space representations are used in the 
recognition and memory of objects, with visual information largely being processed down 
the ventral occipitotemporal stream [30, 31]. Since the ventral stream processes visual 
information to identify objects as opposed to direct movements in response to visual stimuli 
(which is processed down the dorsal stream), studying the effect of PD on perceptions 
processed by the ventral stream may provide evidence that visual processing independent 
of motor activity is abnormal in PD, helping to explain phenomena occurring in PD that 
utilize this processing stream [30]. Movement abnormalities like FOG and environmental 
navigation deficits in PD may be caused in part by inaccurate representations of visually 
perceived objects [15, 17–19].  Individuals with PD also show impairments in object 
recognition and accurate recognition of some facial emotions [32–35]. The above-
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mentioned deficiencies occurring in PD all utilize allocentric visual displacement 
information, using distances between objects and object features to create the full 
representations necessary for accurate recognition. This provides evidence that there may 
be disturbances in the ventral occipitotemporal visual processing pathway in PD.  
The current study has sought to answer three research questions.  The main 
objective of this study (the first research question) was to explore potential visual 
allocentric displacement perception abnormalities occurring in PD independent of motor-
responses and specific object-related memories. The results provide insight into the 
potential ventral visual processing abnormalities occurring in PD. This is building on 
preliminary work which showed a small sample of PD patients had impairments in this 
perception, prompting further, more in-depth investigation.  In addition, in this work (as 
the second research question) we examine the effect that levodopa (half-life: 0.5-1.5 
hours) medication and DBS of the subthalamic nucleus have on allocentric visual 
displacement perception. Early-stage PD patients not currently utilizing PD therapies 
known as “de novo” PD patients were also examined, allowing for analysis over a range 
of PD disease stages. Levodopa is a common first-line treatment that generally improves 
motor dysfunction occurring in PD. However, it has variable effect on the non-motor 
features [3]. This is exemplified in the visual system through improvements in colour 
contrast perception after levodopa administration and detriments in the proprioceptive 
perception of arm displacements [26, 36]. DBS has proven to be an effective late-stage PD 
treatment, specifically when levodopa side effects such as dyskinesia and motor 
fluctuations are severe [37]. DBS in general elicits effects similar to levodopa (when it is 
optimally functioning), with it also displaying varying therapeutic effects depending on the 
non-motor symptom [38]. As levodopa and DBS can improve, impair or have no effect on 
a given non-motor symptom, its effect on visual allocentric displacement perception was 
unknown. This provided further motivation for the study to investigate the positive or 
negative effects of these PD therapies on allocentric visuospatial perception. The third 
research question that was investigated deals with linearity between perceptual accuracy 
and stimulus magnitude, an important perceptual trend consistently occurring in healthy 
individuals.  This trend was first observed in the nineteenth century when E.H. Weber 
sought a method to quantify perceptions independent of the perceptual modality. Based on 
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his studies, the DL of weight perception was found to be related to stimulus intensity as a 
linear function [39].This work, continued by G. Fechner, has led to Weber’s Law, which 
states that the ratio of an individual’s DL (amount of magnitude change necessary to 
discern a stimulus from a different stimulus of fixed magnitude [standard stimulus]) to the 
standard stimulus is constant [40]. The quantifiable value of Weber’s Law, WF, is defined 
as WF = DL/S, where S represents the standard stimulus magnitude. Weber’s Law has been 
validated in a large number of tested modalities [39, 40]. It is widely accepted that 
perceptions of healthy humans measured by WF have a linear relationship, following 
Weber’s Law. Motivated by this, the current study measured participant WF to analyze the 
linearity of visual displacement perception, evaluating if individuals with PD display linear 
relationships in allocentric displacement perception of different stimuli magnitudes. To our 
knowledge this is the first time WF is used to evaluate perceptual capabilities of PD 
patients. Its use was motivated by the observation of potential underlying phenomena 
regarding the effects of PD therapies which cannot be observed through the direct 
measurement of absolute changes in perceptual capability. If validated in this study this 
could be used as a strong tool to investigate the effect of PD and dopaminergic medications 
deeper with regards to its potential benefit for not only perceptual ability, but also on the 
underlying perceptual patterns seen through perceptual linearity.  
3.2 Methods 
3.2.1 Participants 
Thirty-seven patients with middle- to late-stage PD (30 male, 7 female) and 15 healthy, 
age-matched controls (12 female, 3 male) with no known neurological or psychiatric 
disorders participated in the study. The PD patients were recruited from the Movement 
Disorders Program at London Health Sciences Centre, University Hospital in London, 
Ontario, Canada, where they were diagnosed and regularly treated. All patients fulfilled 
the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria. Of the 37 PD patients, 
25 were treated using levodopa medication daily.  At the beginning of the experiment the 
PD patients refrained from taking Levodopa for at least 12 hours, ensuring they were 
completely OFF Levodopa. After the patients performed the experiment in OFF Levodopa 
conditions, they were administered 300 mg of levodopa (unless their regular dose was 100 
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mg or lower, in which case they were administered 200 mg). None of the patients had 
dyskinesia with this acute dose.  The patients conducted the experiments ON and OFF 
levodopa on the same day, with a break of an hour between drug administration. Motor 
symptoms were assessed ON and OFF levodopa using section 3 (motor sub-scale) of the 
UPDRS. Six of the PD patients were using DBS therapy. If these individuals were also 
using levodopa they were asked to refrain from using the medication the day of testing. 
When the patients using DBS entered the lab their DBS device was turned OFF. After a 
45-minute waiting period they carried out the examinations in the same fashion that 
patients using levodopa did. After completing the first round of experiments their DBS 
device was turned back ON to the exact same parameters it was set to when the patient 
arrived for testing. De novo PD patients (n = 6) only had to carry out the experiments once 
as they were not using any PD therapies. Neurological assessment of PD patients was 
conducted using the MoCA [41]. Visual assessments for visual acuity (using reading tasks 
and the Snellen eyechart), smooth pursuit and saccades were performed on all patients by 
an experienced clinician. Patients were excluded from the study if they displayed visual, 
visuomotor or substantial cognitive impairments (MoCA < 25). Furthermore, PD patients 
experiencing PD-VH were excluded from the study. Parkinson’s Disease patients using 
pharmacological medication other than levodopa were also omitted from the study. The 
study protocol for this work was approved by the Research Ethics Board of the University 
of Western Ontario (REB# 107253). All experiments were conducted in accordance with 
the Declaration of Helsinki, as well as the Tri-Councel Policy Statement of Ethical Conduct 
for Research Involving Humans in Canada. All participants provided informed consent 
regarding their participation in the study. Furthermore, the participant displayed in Fig. 3.1 
provided consent allowing for their image to be used in publications of the research. 
3.2.2 Testing Apparatus 
Participant visual input for the tests was solely displayed on a LG Flatron W2242PM 22-
inch visual monitor (resolution: 1680x 1050). Participants sat in a comfortable, upright 
position 2 feet in front of the computer monitor (Fig. 3.1). Both the height of the chair and 
monitor were adjusted for optimum viewing.  Each participant and the examiner were in 
an isolated room, minimizing auditory and visual distractions. The visual perception test 
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was run in a graphics environment designed at CSTAR and connected to a Matlab-
Simulink program controlled by the experimenter. 
 
 
Figure 5: Testing apparatus and displacement perception experiment. The perceptual 
task was conducted on the LG Flatron W2242PM 22-inch (resolution 1680 x 1050) 
computer monitor at a comfortable viewing position for the participant, who is sitting 
approximately 2 feet away from the monitor. The testing room has only the participant and 
experimenter, with excess stimuli (such as sounds, distracting visual) minimized. To the 
right an illustrative example of the allocentric visual displacement perception task with 
each image-pane showing a specific time window in a single trial on the computer monitor 
viewed by the participant. In each trial the participant compares a pair of white to green 
circle displacements (only one displacement shown here). The participant verbally answers 
which displacement distance they perceived to be greater. The example trial begins with 
Image 1 being shown for 1 second, followed by Image 2 being shown for one second. After 
a 1 second period where the screen is blank, a similar process is repeated, however the 
displacement distance (D) is different. It should be noted that the red line is not shown in 
the experiment. Displacement (D) is used in this figure to show the displacement distances 
that are estimated by the participant (and compared to another circle displacement. 
 
3.2.3 Analysis 
Initially the correct and incorrect patient responses from the experiment were computed for 
each comparison value of a given standard stimulus. This data was input to the Psignifit 
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4.0 third quality party Matlab toolbox, which produced a cumulative Gaussian distribution 
psychometric function [42].  The participants’ PSE for both standard stimuli were 
calculated by this toolbox. The UT and LT signify the magnitude of displacement that was 
discerned from the standard stimulus 75% of the time [39], and was obtained through 
analysis of the psychometric function, described in Fig. 3.2. As seen in Fig. 3.2, the DL 
was calculated by subtracting the LT from the PSE, of the PSE from the UT (both yielding 
the same result due to function symmetry). The DL signifies the difference in stimulus 
magnitude necessary to differentiate it from the standard stimulus. Thus, smaller DLs 
signify better perceptual ability. Datum points were considered outliers and omitted from 
analysis if they were 1.5∗ IQR above the third quartile, or 1.5 ∗ IQR below the first quartile. 
3.3 Results 
3.3.1 Demographic Data, PD Related Clinical Characteristics 
In this study, 37 PD patients in total were tested; 25 (22 male, 3 female) using levodopa, 6 
(4 male, 2 female) using DBS, 6 (4 male, 2 female) de-novo patients, and 15 control 
participants (12 female, 3 male) were included. All participants were recruited from the 
Southern Ontario region. Demographic and clinical data for the PD patients are shown in 
Table 3.1. All patients were examined for oculomotor deficits by an experienced clinician 
and only those without deficits were recruited. 
3.3.2 PD vs. Control Displacement Perception Findings 
The DL was the main descriptor used to quantify the perception of participants. The DL 
signifies the change in magnitude necessary to perceptually differentiate a stimulus from 
the standard stimulus.  Smaller DLs signify increased perceptual sensitivity (Fig.  3.2).  The 
task to measure displacement perception is displayed in Figure 3.1.  The results of PD and 
control participants were fit to a cumulative Gaussian distribution, produced using the 
Psignifit 4.0 third party Matlab toolbox (as seen on Fig. 3.2). The individual cumulative 
Gaussian distribution curves produced by a certain participant in a certain condition display 
an inverse relationship between subject DL and curve slope, with greater slopes and 
function shifts implying impaired perception (Fig. 3.3). The paired two -tailed t-test was 
utilized for statistical analysis of PD patients, comparing their perception ON and OFF 
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levodopa.  The unpaired (independent samples) two-tailed t-test was used for comparisons 
between PD and control groups. 
 
Table 3.1: Demographic and clinical data for PD patients. Abbreviations: MoCA – 
Montreal Cognitive Assessment; UPDRS – Unified Parkinson’s Disease Rating Scale  
Demographic Data Levodopa DBS De Novo Control 
Number  25 6 6 15 
Age (years) 70.04 ± 6.80 55.16 ± 8.99 74.17 ± 3.97 67.26 ± 9.04 
Sex (m/f) 22/3 4/2 4/2 3/12 
Total Years of Education 13.4 ± 2.14 13.33 ± 2.50 13.00 ± 1.67 14 ± 1.79 
Clinical Data 
MoCA (out of 30) 26.68 ± 2.17 26.67 ± 3.08 27.83 ± 2.14 27.13 ± 1.50 
UPDRS motor sub-scale 
OFF Therapy 
23.92 ± 6.69 34 ± 10.51 22.33 ± 7.91 N/A 
UPDRS motor sub-scale 
ON Therapy 
14.72 ± 6.07 22.33 ± 7.91 N/A N/A 
UPDRS motor sub-scale 
OFF vs. ON Difference 
9.20 ± 5.09 21 ± 5.62 N/A N/A 
 
 
Figure 6: Individual Cumulative Gaussian Distribution examples used for subject 
analysis regarding displacement perception abilities. Subject DL was analyzed by 
subtracting the PSE from the Upper Threshold (UT; or subtracting the Lower Threshold 
[LT] from the PSE). The UT and LT are the points of the function which the subject 
answered correctly 75% of the time for a given standard stimulus. Larger DLs signify 
decreased perceptual sensitivity. 
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Figure 7: Displacement Perception Gaussian distributions showing perceptual 
performance of individual PD participants using Levodopa. Sub-figures categorized 
by therapeutic state and standard stimulus. Curves are colour coded based on participant 
DL (which is inversely proportional to function slope) for a certain condition. Curves that 
are more blue belong to participants displaying lower DL’s (greater slopes) and thus 
having better perceptual abilities, with red/orange curves signifying the opposite. 
 
For the displacement perception experiment, two different displacement 
magnitudes were used, with the standard stimulus for smaller magnitudes being 10 cm, and 
the standard stimulus of larger magnitudes being 17.5 cm. When comparing all PD patients 
to control participants, there were no abnormalities in displacement seen at the smaller 
standard stimulus between individuals with Parkinson’s disease and control individuals 
OFF their respective therapies (the average DL for PD patients OFF their therapy was 
1.6944 ± 0.48; the average DL for control participants was 1.6026  ± 0.58; p-value = 0.595) 
and ON their respective therapies (the average DL for PD patients ON their therapy was 
1.5037 ± 0.47; p-value = 0.566) (Fig. 3.4). However, for the larger tested standard stimulus 
of 17.5 cm, PD patients displayed significant impairments in visual displacement 
perception OFF of their respective therapies (the average DL for PD patients OFF their 
therapy was 2.2207 ± 0.75; the average DL for control participants was 1.6956 ± 0.44; p-
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value = 0.006), as well as significant impairments while ON their PD therapies (the average 
DL for PD patients ON their therapy was 2.1043 ± 0.78; p-value = 0.033) (Fig. 3.4). 
Figure 8: Displacement Difference thresholds of all PD patients compared to control 
participants. The standard stimulus of 10 cm is displayed on the left, and 17.5 cm on the 
right; with boxplots related to PD patients OFF and ON their respective PD therapies 
compared to control participants. The red lines are the median DL for each group. The bars 
represent the data spectrum. PD patients did not show any impairments in displacement 
perception at the standard stimulus of 10 cm ON or OFF of PD therapies. However, there 
were significant impairments seen at the standard stimulus of 17.5 cm OFF PD therapies 
(p-value =0.006) and ON PD therapies (p-value = 0.033). 
 
Considering only the PD patients utilizing levodopa medication for the standard 
stimulus of 10 cm, the average DL for PD patients OFF levodopa was slightly and 
insignificantly greater (p-value = 0.954) than that for control participants (the average DL 
for patients OFF levodopa was 1.6132 ± 0.49; the average DL for control participants was 
1.6026 ± 0.58). PD patients also showed slightly, however insignificantly increased DLs 
(p-value = 0.372) when they were ON levodopa compared to the tested controls (the 
average DL for patients ON levodopa was 1.4115 ± 0.36) (Fig. 3.5). Thus, at the smaller 
magnitudes of displacement there was no observed perceptual impairments of 
displacement in PD patients both ON and OFF levodopa. For the larger tested standard 
stimulus (i.e., 17.5 cm), the DL of PD patients OFF levodopa was significantly greater (p-
value = 0.041) than control participant DLs (the average DL for patients OFF levodopa 
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was 2.0892 ± 0.68; the average DL for control participants was 1.6956 ± 0.44). In addition, 
there was a relatively strong trend (p-value = 0.120) regarding greater DLs for PD patients 
ON levodopa compared to control participants (the average DL for patients ON levodopa 
was 2.0318 ± 0.79) (Fig. 3.5). Thus, at the greater tested magnitudes individuals with PD 
showed significant perceptual impairments in displacement ON and OFF levodopa 
compared to the tested controls. 
 
 
Figure 9: Displacement difference thresholds comparing control subjects to PD 
patients using Levodopa. DL’s obtained through displacement perception examination 
with the standard stimulus of 10cm being shown on the left and of 17.5 cm on the right. 
The red lines are the median DL for each group. The bars represent the data spectrum. 
Regarding the standard stimulus of 10 cm, there were no significant differences in DLs 
observed between PD patients OFF Levodopa and controls, PD patients ON levodopa and 
controls, and PD patients ON and OFF levodopa. For the standard stimulus of 17.5 cm, 
significant differences in DL were observed between PD patients OFF Levodopa and 
controls (p-value = 0.041), and a relatively strong trend regarding increased DLs between 
PD patients ON levodopa and controls (p-value = 0.120) were also seen. 
 
Levodopa medication did not elicit any significant effects on the perception of 
displacement.  Regarding the standard stimulus of 10 cm, an insignificant trend towards 
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reduced DLs was observed after the patient received levodopa (the average DL of patients 
OFF levodopa was 1.6088 ± 0.51; the average DL of patients ON levodopa was 1.4357 ± 
0.56). In addition, for the standard stimulus of 17.5 cm there was a slight, but insignificant 
increase in DL (p-value = 0.655) after the participants received levodopa (the average DL 
of patients OFF levodopa was 1.9539 ± 0.59; the average DL of patients ON levodopa was 
2.0318 ± 0.79) (Fig. 3.5). 
3.3.3 Displacement Perception Linearity 
To assess correlations in the WF of the two tested stimuli magnitudes the Pearson 
correlation coefficient was used. Typically, it is expected that there will be a linear 
relationship between the WF of different standard stimulus magnitudes (based on Weber’s 
Law), which is signified by substantial correlations between WFs of different standard 
stimuli. This study shows that for the control group, there was very strong correlation 
between the WF of the standard stimuli (Pearson correlation (R): 0.928, p-value < 0.001). 
When comparing all PD patients OFF their respective therapies together, they did not show 
a significant correlation between WFs of the tested standard stimuli (R = 0.250, p-value = 
0.135). However, when all PD patients were using their respective therapies, there was a 
significant correlation seen between the WFs (R = 0.762, p-value < 0.001). When 
specifically looking at the PD patient group that was using levodopa, significant 
correlations were not observed for the WF of different standard stimuli when OFF levodopa 
(Pearson correlation: 0.235, p-value = 0.258). When these PD participants were 
administered levodopa, strong correlations were observed between the WFs of different 
stimuli (Pearson Correlation: 0.821, p-value < 0.001) (Fig. 3.6). The above is summarized 
in Table 3.2. 
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Figure 10: Correlations between participant WF at the standard stimuli of 10 and 
17.5 cm. The red line signifies the line of best fit for the correlation data points. Points that 
have a high similarity between their x and y axis values signifies that the participant 
followed Weber’s Law, displaying little to no difference in the WF calculated at the 
standard stimuli of 10 cm and17.5 cm. Correlation plots for DBS and de-novo PD patients 
are not shown due to small sample sizes (n = 6 for each group) 
 
 
Table 2.2: Results of correlations in WFs calculated at the standard stimuli of 10 cm 
and 17.5cm 
Participant Group Correlations in WFs of Different 
Standard Stimuli Magnitudes (Pearson 
Correlation [R]; p-value) 
Control (n = 15)  R = 0.928; p < 0.001 
All PD Patients OFF respective therapies 
(n = 37) 
R = 0.250; p = 0.135 
ALL PD Patients ON respective therapies 
(n = 37) 
R = 0.762; p < 0.001 
PD Patients OFF Levodopa (n = 25) R = 0.235; p = 0.258 
PD Patients ON Levodopa (n = 25) R = 0.821; p < 0.001 
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3.4 Case Study A: Deep Brain Stimulation 
Besides the results given in previous sections, in this work, a pair of small sample sized 
groups of patients using either DBS therapy or not using any PD therapies (early stage de-
novo patients) were also analyzed as case studies. The intention of these case studies were 
to observe potential trends regarding the visual displacement perception abilities of early 
stage and late stage PD patients (de novo and DBS patients respectively), as well to see if 
any perceptual effect arose from the use of DBS. Due to the small sample sizes for these 
two groups the statistical tests act more so as indicators of trends rather than confirmation 
that certain differences are occurring between certain populations. The Gaussian 
distributions representing participant perceptual abilities are displayed on Fig. 3.7.  
When looking at DLs between control participants and PD patients using DBS at 
the standard stimulus of 10 cm, PD participants displayed on average greater DLs (p-value 
= 0.032) than controls when OFF of DBS (the average DL for patients OFF DBS was 
2.0702 ± 0.29). However, when ON DBS, there was only a slight, non-significant increase 
in DLs (p-value = 0.976) for PD patients compared to controls (the average DL for patients 
ON DBS was 1.60792 ± 0.20). With regards to the standard stimulus of 17.5 cm, patients 
OFF DBS displayed significantly greater DLs (p-value = 0.025) compared to control 
participants (the average DL for patients OFF DBS was 2.9901 ± 0.86). At the larger 
standard stimulus, small, insignificant increases in DLs (p-value = 0.158) were seen for PD 
patients on DBS compared to controls (the average DL for patients ON DBS was 2.347 ± 
0.94) (Fig. 3.8). DBS patients displayed overall impairments in displacement perception, 
specifically when they were not using their treatment. PD patients using DBS in their OFF 
state displayed a strong correlation between the WFs of different standard stimuli 
(Pearson’s Correlation: 0.972, p-value = 0.001). However, when these patients were ON 
DBS, they did not display any significant correlations in the WFs of the different standard 
stimuli (Pearson Correlation: 0.384, p-value = 0.452). 
For these PD patients using DBS, no significant differences in DLs were seen 
between ON and OFF DBS states. At the smaller standard stimulus there was an 
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insignificant decrease in DLs (p-value = 0.167) when patients were ON DBS (the average 
DL of patients OFF DBS was 2.0609 ± 0.17; the average DL for patients ON DBS was 
1.5749 ± 0.21).  At the larger tested magnitudes (standard stimulus 17.5 cm) there was 
again an insignificant decrease in DLs (p-value = 0.560) when the patients were using DBS 
(the average DL for patients OFF DBS was 2.9907 ± 0.86; the average DL for patients ON 
DBS was 2.5819 ± 0.37) (Fig. 3.8). Although there were decreases seen when PD patients 
were using their respective therapies (especially for those on DBS), these improvements in 
DL were not significant. It should be noted that a strong trend towards reduced DLs was 
observed when participants were ON DBS. However, due to the small sample size of the 
DBS PD group (n = 6) it is possible that the statistical analysis is not representative of the 
therapy’s perceptual improvements. In all but one of the patients using DBS, reduced DLs 
were observed when ON DBS at both standard stimuli magnitudes, further promoting the 
possibility of unrepresentative statistical outcomes. 
3.5 Case Study B: de Novo Patients 
The final patient group that was tested was the early stage de novo PD patients, who were 
not using any PD therapies at the time of testing. The Gaussian distributions representing 
participant perceptual abilities can be seen on Fig. 3.7. For the smaller standard stimulus 
of 10 cm, there was a slight, insignificant increase in the DLs (p-value = 0.749) of de novo 
PD patients compared to the control group (the average DL for de-novo patients was 1.6787 
± 0.44).  At the larger tested standard stimulus of 17.5 cm, de novo patients displayed a 
strong (but insignificant) trend towards greater DLs (p-value = 0.158) compared to the 
control group (the average DL for de-novo patients was 2.3474 ± 0.94) (Fig. 3.8). Thus, 
early stage PD patients did not display significant differences in PD compared to the 
controls. The de novo PD participants did not show any significant correlations between 
the WFs of the tested standard stimuli (Pearson Correlation:  0.412, p-value = 0.416). All 
PD groups displayed discrepancies in Weber’s Law in some therapeutic state, contrasting 
the control group which had a strong correlation between the WFs (Fig. 3.6). To reiterate 
again, the statistical analysis of the case studies are not necessarily representative of the 
patient subgroup populations due to their small sample size, however the trends that were 
found present interesting information on how the patients of different disease stages, 
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utilizing different treatments are affected by the disease. The above findings regarding 
perceptual linearity is summarized in Table 3.2, with the observations regarding perceptual 
ability being summarized in Table 3.3. 
 
Table 3.3: Results for DL % increases and comparison of means via two-tailed t-
tests for the Levodopa, DBS and De Novo PD groups 
Compared Participant 
Groups (x vs. y) 
Increase in DL (%x > y); t test (x vs. y) p-value 
 Levodopa (n 
= 25) 
DBS (n = 6) De Novo (n = 6) 
PD OFF vs. Control (Standard 
Stimulus: 10 cm)  
0.6614%; p = 
0.954 
29.19%; p = 
0.032 
4.755%; p = 
0.749 
PD OFF vs. Control (Standard 
Stimulus: 17.5 cm) 
23.21%; p = 
0.004 
76.34%; p = 
0.025 
1.384%; p = 
0.158 
PD ON vs. Control (Standard 
Stimulus: 10 cm) 
-11.64%; p = 
0.372 
0.3351%; p = 
0.976 
N/A 
PD ON vs. Control (Standard 
Stimulus: 17.5 cm) 
19.83%; p = 
0.120 
38.44%; p = 
0.158 
N/A 
PD OFF vs. PD ON (Standard 
Stimulus: 10 cm) 
12.06%; p = 
0.164 
28.75%; p = 
0.167 
N/A 
PD OFF vs. PD ON (Standard 
Stimulus: 17.5 cm) 
3.987%; p = 
0.655 
27.40%; p = 
0.56 
N/A 
 
3.6 Discussion 
This study investigated allocentric visual displacement perception while excluding goal-
directed motor responses for those with PD. In addition, the effect of levodopa and DBS 
medication and perceptual linearity was investigated. The PD patient group showed overall 
impairments in displacement perception compared to controls.  The observed deficiency 
cannot be due to oculomotor deficiencies since all participants were examined for these 
malfunctions before conducting the tests. Furthermore, PD patients with PD-D and PD-VH 
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Figure 11: Displacement Gaussian distributions of individual participants 
categorized by disease state, therapeutic state and standard stimulus. Curves are 
colour coded based on the participants DL (which is inversely proportional to function 
slope) for a certain condition. Curves that are more blue belong to participants displaying 
lower DL’s (greater slopes) and thus having better perceptual abilities, with red/orange 
curves signifying the opposite. 
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Figure 12: Difference thresholds obtained through displacement perception 
examination of DBS and de novo patients. The standard stimulus of 10cm is shown on 
the left and 17.5 cm on the right. The red lines are the median DL for each group. The bars 
represent the data spectrum. Regarding the standard stimulus of 10 cm, patients using DBS 
had significantly greater (p-value = 0.032) DL’s than controls while OFF DBS; however, 
when ON there were no significant differences. There was also no significant difference 
between patients ON and OFF DBS. De novo patients did not display patients using DBS 
had significantly greater DLs than controls when OFF DBS (p-value = 0.025) as well, 
however no significant differences were seen in DLs between patients ON DBS and 
controls. There were no significant differences between de-novo patients and control 
patients at this standard stimulus. Levodopa and DBS did not elicit significant changes in 
DL for PD patients. 
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were omitted from the study. Therefore, the observed perceptual abnormalities are not 
likely due to cognitive deficit. Thus, the current study showed that allocentric visual 
displacement perception is abnormal in mid-stage PD patients (using levodopa), and late 
stage PD patients (using DBS), and that observed deficiencies are not likely arising from 
the motor or sensorimotor integration complications of the disease due to the task isolating 
perception from motor activity. The early stage PD patients did not however show 
significant impairments in the visual displacement perception task. 
In general, PD patients showed increased DLs – signifying decreased perceptual 
sensitivity – in visual displacement perception compared to the control group for the larger 
tested displacement magnitudes. Previous research has shown that patients with PD-D 
and/or PD-VH (both common in late stage PD) displayed impaired visual memory and 
object perception [43, 44]. Both vision-based memories and perception of specific objects 
are neurally processed through the ventral occipitotemporal processing stream [30]. 
However, it cannot be determined if executive, visuospatial and memory impairments 
occurring in PD-D, and visual abnormalities due to PD-VH were responsible for the 
observed visual memory and object perception deficits, or if the findings were caused by 
deficits in the ventral processing stream [30, 31, 45, 46]. The current study however 
provides evidence that impairments in the occipitotemporal visual processing stream occur 
in mid-stage PD before PD-D and PD-VH symptoms arise. It is important to note that 
although working memory and attentional deficits are well noted symptoms of PD [47, 48], 
it is unlikely that these contributed to the observed perceptual abnormalities for the 
levodopa and de novo PD groups as no deficits were seen at the smaller displacement 
magnitudes that were tested. This further provides new evidence that the observed 
allocentric displacement perception dysfunctions may be arising due to disruptions in the 
ventral occipitotemporal pathway. Our findings along with past work showing impairments 
of object identification and recognition of facial features and emotions [32–35] might 
indicate dysfunction in neural regions along the ventral visual processing stream that 
respond to certain classes of objects (and specific objects/faces) such as the inferior 
temporal cortex and fusiform face area [49, 50]. It should be noted patients that were 
utilizing DBS therapy did however show deficits in the perception task at both testing 
magnitudes. As individuals in this study that were using DBS were at a later stage of the 
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disease, it is possible that the increased disease severity contributed to memory and/or 
attentional deficits which lead to decreased performance at all testing magnitudes. 
However, increasingly severe PD symptoms may lead to an increasingly impaired 
processing of visual displacements via the occipitotemporal pathway, leading to a broader 
range of perceptual deficits. This note is further motivated due to all PD patients conducting 
memory tasks, with those showing substantial deficits being excluded from the study. 
Levodopa and DBS were shown to have no significant effect on the tested visual 
displacement at both of the tested standard stimuli, aligning with past studies suggesting 
these therapies predominantly benefit PD motor symptoms, having a minimal effect on 
non-motor symptoms [3]. Both levodopa and DBS modulate dopaminergic neural 
pathways of the BG, however, neural dysfunction in PD is not limited to dopaminergic 
dysfunction in the BG [37]. Non-dopaminergic neural abnormalities (such as cholinergic, 
noradrenergic and glutamatergic dysfunction) also contribute to PD symptoms [51].  In this 
regard, FOG, which is heavily influenced by improper visuospatial perception, responds 
poorly to dopaminergic treatment [18]. Also, recent work suggests the occurrence of FOG 
is based on improper noradrenergic neural function as opposed to dopaminergic 
dysfunction [52]. As visuospatial processing involves both allocentric and egocentric 
visual perceptions [31], the perceptual abnormalities observed in the current study may 
contribute to the visuospatial deficits seen in PD. This suggestion is further supported by 
the lack of a significant response from levodopa in the current study, which is consistent 
with levodopa’s lack of effect on PD symptoms utilizing visuospatial information (such as 
FOG). Furthermore, past research concluded levodopa did not lead to improvements in the 
object recognition capabilities of PD individuals [53]. Thus, the lack of effect caused by 
levodopa for previously researched visual perceptions utilizing displacement information 
and in our current study suggests the postulated ventral visual processing stream 
impairments in PD are not caused by dopamine related dysfunction. Interestingly, past 
work has suggested that DBS of the subthalamic nucleus lead to impairments in the 
recognition of certain facial emotions [54]. Although accurate facial emotion recognition 
requires much more than just visual displacement perception, this further contributes to the 
idea that the observed perceptual abnormalities are not caused by a dysfunction of 
dopamine dependent BG processes. However, it should be noted that a relatively strong 
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trend regarding reductions in patient DL when ON DBS (compared to when OFF DBS) 
was observed. Furthermore, statistical abnormalities were seen in the DL of DBS patients 
OFF stimulation compared to controls, with no statistical observations seen when these 
patients were ON stimulation (Fig. 3.8). Thus, it appears DBS might cause improvements 
of visual displacement perception abnormalities seen in PD patients; however, due to the 
small sample size of PD patients using DBS, future work should further investigate this 
therapies effect on the tested perception.  
In the current study, patients with PD in general did not show linear perceptual 
capability in visual displacement perception. To the best of our knowledge this is the first 
time that linearity of a perceptual ability and the effect of dopaminergic medication has 
been investigated in patients with PD. Although displacement perception of control 
participants was consistent with Weber’s Law, PD patients deviated from this in some 
cases, suggesting the possibility of nonlinearity in perceptual capabilities of PD patients.  
According to the analog coding hypothesis mental processes occur in a continuum, 
meaning higher-level mental processes function similarly to related lower-level processes, 
follow the same laws, and display similar attributes [55]. It was further shown that some 
cognitive processes exhibit attributes similar to those found in related sensory and 
perceptual processes [55]. Regarding visual perception of displacement, both accurate 
visual perception and accurate processing of visual information in higher visual areas is 
needed to accurately perceive visual displacements.  As the visual stimuli of both the 
smaller and larger displacement magnitudes per trial are identical (two white and two green 
circles on a black background), it is likely that discrepancies in the linearity of Weber’s 
Law occur in higher visual processing areas. This further suggests that the displacement 
perception abnormalities may be rooted in dysfunctional ventral visual processing in PD, 
causing deviations from perceptual linearity seen in healthy individuals. The results also 
imply that the observed perception abnormalities were not caused by memory and attention 
problems, as this should lead to deficits at both tested standard stimuli. Interestingly, when 
patients were utilizing levodopa they showed very strong perceptual coherency, while OFF 
Levodopa no correlations between the WF of the tested standard stimuli were seen. This 
appears to indicate a role of levodopa in visual displacement perception, possibly regarding 
a “tightening” of an individual’s perceptual boundaries, causing more consistent perception 
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across stimulus magnitudes. To further explore the observed perceptual non-linearity 
occurring in PD an increased range of stimuli magnitudes should be tested.  
For this work a graphical tool that can be used to test visual perceptions was 
designed and validated. The tool is easily modified, allowing for the testing of various 
perceptual modalities, stimulus magnitudes and stimulus orientations.  The current study 
can be extended to encompass more orientations and stimuli magnitudes, as well as 
different perceptual modalities to further examine how perceptions are abnormal in PD, 
with future work aiming to assess the use of the graphical tool for diagnostic and disease 
monitoring purposes. Based on the study’s results, perceptions of the larger tested 
magnitudes were abnormal to some extent across disease stages. Although no significant 
impairments were observed in the early-stage de novo PD patients at the larger tested 
standard stimulus, there was a relatively strong trend towards impaired visual displacement 
perception for the standard stimulus of 17.5 cm. Future work should seek to analyze this 
perception over a large time scale, to see if visual displacement perception abilities does 
indeed deteriorate as PD becomes more severe. A study limitation is that similar to most 
ON/OFF levodopa studies, PD patients always conducted the experiment first OFF 
levodopa/DBS, followed by ON levodopa/DBS. As each subject participated in only one 
experimental session, it was necessary that they begin the experiment OFF levodopa, as 
one must refrain from levodopa for 12 hours to be considered in an OFF state. Thus, it is 
possible that participants experienced increased fatigue in their ON state compared to their 
OFF state. However, the hour break between sessions and breaks during testing should 
have provided sufficient mental relief to the participants. 
In summary, allocentric visual displacement perception independent of associated 
movements was assessed in PD ON and OFF levodopa/DBS therapies, as well as in early-
stage patients. Mid- to late-stage PD patients using either levodopa or DBS therapies 
displayed significant impairments in displacement perception of the larger tested 
magnitudes, however these impairments were only seen at the smaller magnitudes in the 
late-stage patients utilizing DBS. The work has revealed visual perceptual impairments in 
PD that are not due to abnormal motor or sensorimotor integration function, suggesting 
that impairments in the ventral occipitotemporal visual processing pathway occur in PD. 
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Future work should further investigate the neurological basis for these abnormalities, as 
well as different perceptual modalities that may be affected in PD.  
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Chapter 4  
4 Vision-based Velocity Perception in Parkinson’s 
Disease: Skewed Perception of the Fabric of Time and 
Space 
This chapter contains the paper (with the same title) to be submitted for journal 
publication. 
4.1 Introduction 
Non-motor symptoms of Parkinson’s Disease (PD) are as common and important as their 
motor counterparts when considering disease related implications on the quality of life of 
those affected, institutionalization costs, and economic burden on the healthcare system 
[1–5].  Although the importance of non-motor symptoms has been noted in the literature, 
the characteristics of these symptoms are yet to be fully discovered. This challenge is 
compounded by difficulties in diagnosis and treatment of PD; thus, the non-motor 
symptoms are often neglected during the process of PD management [1, 6, 7].   Of these 
non-motor disease symptoms, perceptual abnormalities have been noted to occur across 
various sensory systems—sometimes appearing before the onset of motor symptoms—
raising concerns regarding the affected individual’s performance in daily activities such as 
navigation and the operating of vehicles [8–13].  One of the sensory systems primarily 
affected is the visual system, with abnormalities ranging from colour and contrast 
perceptual deficits to visual recognition, spatial, and vision-based motion perception 
impairments [12–15]. The accurate visual perception of velocity is fundamental for 
navigation, mobility, and motor control, with deficits substantially impacting an 
individual’s quality of life. Although direct measurements of velocity perception can be 
made when there is an interaction between a human limb and the moving object (for 
example measuring muscle spindle activity), similar direct measurements are not currently 
available for the visual perception of velocity. A factor for this may be that perceiving the 
speed of visual stimuli may involve the processing of multiple sensory modalities, 
requiring proper timing, judgement of position, information integration, and optimal 
sensory functioning (via the eye). In this work, for the first time, the capability of PD 
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patients is examined regarding the perception of velocity visually, while observing the 
effect of dopaminergic medication and DBS therapy. For this we conducted a visual 
velocity perception task independent of movement for PD patients at different stages of the 
disease who utilized either levodopa, DBS or no therapy, as well as control participants. 
For the first time it is shown that accurate visual perception of an object’s speed is abnormal 
in PD, with impairments extending to early stages of the disease. Furthermore, levodopa 
medication appears to be detrimental to this perception. The linearity in perception is also 
examined and reported. This work not only sheds light on perceptual deficits occurring in 
PD that have everyday implications, but also suggests visual velocity perception as a 
promising modality to be used for disease diagnosis and monitoring in the future. 
4.1.1 Background 
Parkinson’s Disease (PD) is the second most common chronic progressive 
neurodegenerative disease that has been extensively researched, uncovering many motor 
and non-motor symptoms that both significantly impact patient quality of life. However, 
the symptoms targeted for therapeutic intervention, as well as clinical diagnosis and 
monitoring markers have almost exclusively been the motor symptoms, often causing 
treatment outcomes that do not address all disease symptoms [16, 17]. The root cause of 
PD is believed to be major degeneration of dopaminergic neurons at the SNc, leading to 
reduced dopamine levels at the BG, in turn causing heterogeneous motor symptoms [17–
19]. Accordingly, pharmaceutical and surgical interventions seek to restore BG function 
and alleviate disease motor symptoms, often with excellent efficacy [20, 21]. However, the 
non-motor symptoms do not universally respond well to these treatments like motor 
symptoms do. Non-motor symptoms instead display a much more variable response to 
dopaminergic and DBS therapies that can be beneficial, detrimental, or neutral depending 
on the symptom, suggesting neurotransmitters other than dopamine are also involved (and 
functioning abnormally) for some non-motor symptoms [1, 4, 8, 22]. Although there has 
been increased attention given to the importance and extent of non-motor PD symptoms in 
recent years, there is still a substantial lag in the management of non-motor symptoms 
compared to PD motor symptoms. This in many cases leads to non-optimized clinical 
outcomes as non-motor symptoms can be left unnoticed and untreated by practitioners [7].  
110 
 
It is clear that improvements in the understanding of non-motor PD symptoms are 
necessary for improved patient care. This would also help enhance patient quality of life 
as adverse events related to navigation and environmental interactions that contribute to 
everyday living (from crossing a street to driving a car) would be directly clinically 
monitored and addressed. By understanding the characteristics and variability of non-
motor symptoms clinicians will be better equipped to diagnose, assess, and treat patients. 
It can also provide new information for developing new treatments and improve upon the 
early diagnosis and comprehensive monitoring practices of PD.  
4.1.2 Current Study Rationale and Procedure 
To address the current uncertainty regarding the perceptual abilities of PD patients 
for vision-based velocity, as well as uncertainties regarding the neural processing of 
velocity in general, a perceptual task was carried out on a computer-generated graphical 
tool capable of quantifying perceptual abilities independent of movements. It should be 
noted that there is a lack of studies that focus specifically on visual perceptions of motion 
that function independently from goal-directed movements and motor-control, causing 
results that are influenced by degraded motor functioning occurring in PD [23]. Although 
accurate perception of object velocity is imperative for conduction of several activities of 
daily living such as the accurate navigation through our dynamic world, obstacle 
avoidance, and the operating of automobiles, vision-based velocity perception has yet to 
be analyzed in PD. In this work, vision-based velocity perception is examined for 25 
patients with PD utilizing levodopa therapy, 6 PD patients using subthalamic DBS therapy, 
6 de novo patients in early stages of PD, as well as 17 age-matched control participants. 
All participants conducted occulomotor and cognitive diagnostic testing, ensuring those 
included in the study did not display substantial visual or cognitive deficits that could affect 
the main experiments results. The primary visual velocity perception examination was 
designed to solely test perceptual ability (without any goal-directed motor inputs) through 
a two-forced alternative choice discrimination test composed of 200 trials according to the 
method of constant stimuli described by Gescheider et al. [24].  
In each trial of this study, two circles (each moving at a constant but different 
vertical velocity) were presented in series, with the subject verbally answering (without 
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any time constraint) which circle they perceived to be moving the fastest. One of two 
standard stimuli (10 cm/s or 25 cm/s) were present in each trial at random, with 5 greater 
and 5 lesser comparison speed magnitudes compared 10 times to each standard. Upon 
completion of the velocity discrimination task subject responses were broken up based on 
standard stimulus and input to the psignifit 4 psychometric measurement toolbox, i.e., 
psignifit 4 [25], which is a third party Matlab toolbox used to produce a cumulative 
Gaussian distribution used for perceptual quantification of each standard stimulus. Patients 
using either levodopa or DBS conducted the velocity discrimination task both ON and OFF 
their respective therapy, allowing for the analysis of therapy’s efficacy on the studied 
perception. The subject’s DL for each standard stimulus and therapeutic state was obtained 
through analysis of Gaussian distributions (Fig. 4.1), indicating the stimulus magnitude 
needed by an individual to discern said comparison stimulus as different from the tested 
standard stimuli [24].  An individual with a smaller DL for a given perceptual modality 
will have increased perceptual sensitivity, thus displaying better perceptual abilities. This 
allowed for the quantification and comparison of visual velocity perceptual abilities 
between participants and participant states. 
4.2 Results 
4.2.1 Velocity Perception in PD 
Firstly, the mean DLs of all PD patients OFF and ON their respective therapies to control 
participants. PD patients showed statistical impairments in visual velocity perception of 
speeds compared to the standard stimulus magnitude of 10 cm/s.  The DLs of control 
participants (mean DL: 1.24 ± 0.39) were significantly smaller than those of all tested PD 
patients OFF of their therapies (mean DL: 1.62 ± 0.47; control vs. PD OFF p-value:  0.008). 
PD patients ON their therapies (mean DL: 1.81 ± 0.56) again displayed perceptual 
impairments compared to healthy individuals (control vs. PD ON p-value:  0.001) (Fig. 
4.2). When refining the patient groups based on their therapy usage these smaller PD 
participant groups still displayed impaired velocity perception for the smaller magnitude 
speeds. Considering the PD patients using levodopa, strong (yet insignificant) trends 
showed impairments in visual velocity perception when OFF therapy compared to ON 
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therapy (mean DL: 1.55 ± 0.52; control vs. PD OFF levodopa p-value:  0.061). When 
participants   were administered (ON)  levodopa,  they  displayed  significant  perceptual  
 
Figure 4.1: Cumulative Gaussian Distribution examples used for subject analysis of 
velocity perception. Subject DL was analyzed by subtracting the Point of Subjective 
Equality (PSE) from the Upper Threshold (UT; or subtracting the Lower Threshold [LT] 
from the PSE). UT and LT are the points of the function which the subject answered 
correctly 75% of the time for a given standard stimulus. Larger DLs signify decreased 
perceptual sensitivity. 
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impairments (mean DL: 1.81 ± 0.62; control vs.  PD ON levodopa p-value:  0.003).  The 
late stage PD patients using DBS to treat their PD displayed significant impairments both 
ON DBS (mean DL: 1.82 ± 0.58; control vs.  PD ON DBS p-value: 0.016) and OFF DBS 
(mean DL: 1.81 ± 0.28; control vs. PD OFF DBS p-value:  0.005). Impairments in velocity 
perception using the smaller standard stimulus extended to the early stages of the disease, 
with significant perceptual impairments seen in de novo patients (mean: 1.75 ± 0.27; 
control vs PD de novo p-value: 0.015) (Fig. 4.3). 
In contrast to the smaller reference stimulus, at higher tested velocities (using the 
standard stimulus of 25 cm/s) there were no statistical differences observed in perceptual 
ability between control and PD participants. The DLs of control participants (mean DL: 
3.85 ± 1.67) did not substantially differ from the DLs of PD patients OFF their respective 
therapy (mean DL: 3.59 ± 1.40; control vs. PD OFF p-value: 0.557) and ON therapy (mean 
DL: 4.06 ± 1.40; control vs.  PD ON p-value:  0.661) (Fig. 4.2).  Considering only patients 
utilizing levodopa medication, no significant differences in perceptual abilities for the 
visual velocity task ON levodopa (mean DL: 4.30 ± 1,74; control vs. PD ON levodopa p-
value:0.407) and OFF levodopa (mean DL: 3.57 ± 1.14; control vs. PD ON levodopa p-
value: 0.551) were observed. Similarly, perceptual abilities of patients using DBS did not 
differ from control participants ON DBS (mean DL: 4.15 ± 1.87; control vs. PD ON DBS 
p-value:  0.710) and OFF DBS (mean: 4.27 ± 2.43; control vs. PD OFF DBS p-value: 
0.639) for the standard stimulus of 25cm/s. Again, this trend persists in the early stages of 
PD, as the DL of de novo patients (mean DL: 3.00 ± 1.00) did not differ significantly from 
control participants (control vs. PD de novo p-value: 0.260) (Fig. 4.3). 
4.2.2 Velocity Perception Linearity 
In this work, to further analyze participants’ perceptual ability perceptual linearity 
was also examined using Weber’s Law. Weber’s Law states that an individual’s DL is 
directly proportional to the magnitude of the standard stimulus, in that the greater the 
stimulus magnitude the greater the magnitude change necessary to differentiate stimuli. 
This is exemplified through consistent correlations in the WF (defined as WF = DL/S, 
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where S is standard stimulus magnitude) for standards differing in magnitude [24]. Weber’s 
Law has been validated for healthy individuals over a wide range of sensory modalities 
[26, 27]. The effect that PD and levodopa have on perceptual linearity is largely unknown, 
although linearity provides a different means of measurement to assess perceptual abilities. 
In the current work, Pearson correlation analysis of the participants’ WF for the 10 cm/s 
and 25 cm/s standards for a certain therapeutic condition were analyzed, with high 
correlation between WFs signifying perceptual linearity and satisfaction of Weber’s Law.  
The results showed that for the control group there were moderate correlations seen 
between the two WFs (Pearson Correlation [R] = 0.534, p-value: 0.027), signifying their 
accordance with Weber’s Law. Interestingly, when all PD patients were analyzed as a 
group, moderate correlations were also seen in the OFF medication state (R = 0.432, p-
value:  0.008). However, this perceptual coherency was not observed with patients were 
ON their respective therapies, for which a very small, insignificant correlation is observed 
(R = 0.168, p-value: 0.367).  A similar trend was observed when specifically examining 
the performance of patients using levodopa, with Weber’s Law being satisfied in the OFF 
state (R = 0.496, p-value:  0.012), but not the ON state (R = 0.142, p-value: 0.497) (Fig 
4.4). 
 
Figure 4.13: Velocity perception difference thresholds of all PD patients (n = 37) 
regardless of treatment state compared to control participants. The standard stimulus 
of 10 cm/s is displayed on the left, and 25 cm/s second on the right; with boxplots related 
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to PD patients OFF and ON their respective therapies.  The red lines are the median DL for 
each group. The bars represent the data spectrum. PD patients did not show any 
impairments in temporal perception at the standard stimulus of 0.5 seconds ON or OFF PD 
therapy. However, there were significant impairments seen at the standard stimulus of 10 
cm/s OFF PD therapy (p-value = 0.008) and ON PD therapy (p-value = 0.001). 
 
Figure 14: Velocity difference thresholds separated by individual therapies/de novo 
obtained through velocity perception examination. The standard stimulus of 10 cm/s 
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displayed on the left, and that of 25 cm/s on the right. The red lines are the median DL for 
each group. The bars represent the data spectrum.  Regarding the standard stimulus of 25 
cm/s, there were no significant differences in DLs observed between PD patients OFF and 
ON levodopa and DBS compared to controls.  De novo PD patients did not display 
significant differences in DL compared to controls as well.  Although use of DBS did not 
lead to significant changes in the DLs of PD patients, there were significant differences (p-
value = 0.006) elicited by levodopa use.  For the standard stimulus of 10 cm/s, substantial 
differences in DL were observed between PD patients OFF levodopa and controls (p-value 
= 0.061), as well as significant differences when ON levodopa compared to controls (p-
value = 0.003) were also seen. PD patients also significantly differed in perceptual abilities 
when administered levodopa compared to their OFF state (p-value = 0.030). PD patients 
using DBS displayed significant increases in DL when OFF DBS (p-value =0.005), and 
ON DBS (p-value = 0.016). De novo PD patients also displayed significantly greater DLs 
than controls (p-value = 0.015) at the standard stimulus of 10 cm/s. DBS use did not lead 
to significant differences at both tested standard stimuli magnitudes. 
 
 
Figure 15: Correlations between participant WF at the standard stimuli of 10 and 25 
cm/s. Points displaying high similarity between their x and y values signify that the 
participant displayed little to no difference in the WF values at different stimulus 
magnitudes, and thus are in accordance with Weber’s Law. Correlation plots of DBS and 
de novo patients are not shown due to small sample sizes (n = 6 for each group). 
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4.3 Discussion 
The current work has observed deficits in visual velocity perception (independent of related 
movements) occurring in individuals with PD, and the degrading effect of dopaminergic 
therapy on the perception sensitivity and linearity according to Weber’s Law. Interestingly, 
the significant perceptual impairment was statistically validated for the slower tested 
velocities, while comparison with the faster standard stimulus of 25 cm/s did not show 
statistically different perceptual capability compared with the healthy group. A potential 
explanation for this observation could involve the manner that the neural system processes 
vision-based velocity inputs. Considering the mathematical formula for velocity (V), in 
which V = ΔD/T (where D and T signify displacement and time respectively), time 
perception deficits, displacement perception deficits or deficits in multimodal sensory 
fusion could affect the perception of velocity if neural calculations of visual velocity are 
indeed processed in this manner. When considering velocity perception as a problem of 
multimodal information fusion that is neurally complied, impairment of either time or 
displacement would contribute to abnormalities in perceiving velocity. As discussed in 
Chapters 2 and 3, the visual perception of both displacement and time functions abnormally 
in individuals with PD. Thus, abnormalities in the processing of visual velocity may be 
rooted in one, or both of these sensory modalities. Evidence for this phenomenon can be 
seen with temporal deficits as abnormalities were observed in the second, but not 
millisecond range; correlating to deficits occurring at slower velocities with movement 
durations in the second range, but not the greater velocities with movement durations in 
the millisecond range. Also of interest, the administration of levodopa led to detriments in 
velocity perception at both standard stimuli, persisting at the greater standard stimulus (25 
cm/s). Furthermore, perceptual coherency was shown to be disrupted significantly after the 
administration of levodopa for the patients using the therapy. In the past, levodopa 
medication has been shown to have variable efficacy with regard to non-motor symptoms.  
However, it has been suggested that levodopa induced impairments of temporal perception 
are a repercussion of dopamine overdose, in which levodopa concentrations that are ideal 
for treating motor symptoms are detrimental for certain timing procedures [31]. The 
detrimental effects of levodopa on velocity perception further suggests the use of temporal 
information during the neural processing of visual velocity information.  
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The analysis of speed perception in PD has been explored in a few past studies, 
however these works aimed to mimic environmental movement as opposed to object 
movement [32, 33]. Although both environmental movement and object movement are 
controlled by similar neural complexes (the dorsal MST and lateral MST respectively) that 
interact with one another, the information processed by the dorsal MST is used for gauging 
movement of the perceiving individual, while the lateral MST provides details about object 
movement and velocity [34, 35].  As the lateral MST processes object motion information 
to allow the perceiving individual to visually track and interact with the said object, it can 
be assumed that individuals with PD will display abnormalities in MST-related processes 
if the results from the current study are rooted in MST dysfunction. This is indeed the case, 
as PD patients have displayed impairment with the visual tracking and grasping of objects 
in space [36–38]. It should be noted that smooth pursuit functioning is impaired in PD [39], 
possibly signifying oculomotor impairments as the root cause of visual velocity perception 
as opposed to perceptual abnormalities.  However, all patients had diagnostic assessment 
of oculomotor functioning by a trained clinician to ensure no severe abnormalities were 
present. As only one of the standard stimuli had observed abnormalities this further 
suggests a perceptual, and not an oculomotor deficit was responsible for the observations.  
The current work provides evidence that visual perception of objects velocity is 
impaired in PD. This implies an inaccurate representation of an object in space, which 
could be caused by inaccurate estimations of dynamic changes in object position (i.e. 
speed), inaccurate perception of time, or inaccurate fusion. In summary, PD and 
dopaminergic medications can potentially affect perceptions of the fabric of space and 
time, which can directly affect task conduction in this 4th-dimentional coordinate. The 
observed deficit, which may appear early in the disease progression (as shown in the 
current work’s results for de novo patients) presents a concern for those who have 
developed PD but are not yet diagnosed. The greatest concern regarding abnormal velocity 
perception involves the operation of heavy machinery such as vehicles. Past studies 
validate the presence of these concerns as individuals suffering from PD exhibit 
impairments in driving abilities [40–42].  Driving is a complex task that involves attention 
and motor control (both known to be impaired later in PD progression), as well as accurate 
perception of object’s velocities. The latter is a critical aspect which should be 
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systematically investigated early in the disease’s progression to assess the risks brought on 
by the improper perception. The protocol proposed and presented in this work used a 
simple virtual reality environment (which can be easily implemented on any computer and 
other devices such as smart phones) can be considered an in-clinic diagnostic and 
monitoring tool that would be able to provide quantitative measures regarding one’s vision-
based perceptual ability of speed and linearity of this perceptual ability. As mentioned, 
visual perception of velocity appears to be sensitive to deficits in other sensory modalities 
and/or the fusion of sensory information. Considering this, velocity perception 
abnormalities in PD may be magnified compared to temporal, displacement, and sensory 
integration deficits on their own, increasing graphical tool’s sensitivity to neurological 
based perceptual disorders. This motivates further investigation of this modality for early 
diagnosis, monitoring of disease progression, and for better assessment of one’s disease 
induced perceptual risks. It should be noted that the presented velocity perception 
assessment tool is simple to use, flexible with regards to the perceptual modality that is to 
be tested, and does not require much computational power, allowing it to be utilized in 
many clinical and non-clinical settings.  As the graphical tool shows promise for use with 
diagnosis and monitoring of neurological disorders, future work will aim to further validate 
its use through continued perceptual studies to further validate efficacy (specifically with 
early stage patients to analyze its diagnostic potentials), as well as study the effectiveness 
of pairing the tool with other potential disease monitoring and diagnostic tools (such as 
haptic enabled robotic systems). The current work uncovered a vision-based velocity 
perception deficit in PD that potentially has substantial implications and presents a tool to 
systematically assess perceptual deficits occurring during neurological disease. 
4.4 Methods 
4.4.1 Participants 
The study protocol for this work was approved by the Research Ethics Board of the 
University of Western Ontario. All experiments were conducted in accordance with the 
Declaration of Helsinki, as well as the Tri-Council Policy Statement of Ethical Conduct for 
Research Involving Humans in Canada. All participants provided informed consent 
regarding their participation in the study.  Furthermore, the participant displayed in Fig. 
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4.5   provided consent allowing for their image to be used in publications of the research. 
All of the PD participants were recruited through the Movement Disorder Program, at the 
University Hospital, London, Ontario, Canada. This is the care centre at which they were 
diagnosed with PD, receive treatment and regularly monitor the disease. A total of 25 
participants using levodopa (22 male, 3 female), 6 using DBS (4 male, 2 female), 6 de novo 
(4 male, 2 female), as well as 17 age-matched control participants with no known 
neurological disorder were tested. A summary of the demographic and clinical data for the 
patients can be seen in Table 2.1. All patients were from Southern Ontario, and recruited 
at the University Hospital in London, Ontario, Canada. All of the PD patients for this study 
fulfilled the UK Parkinson’s Disease Brain Bank criteria. Patients using levodopa (half-
life: 1.5 hours) were instructed to refrain from medication for at least 12 hours prior to 
assessment, ensuring complete metabolism necessary for OFF testing. Similarly, patients 
using DBS were instructed to refrain from Levodopa use 12 hours prior to assessment, with 
their DBS device being turned OFF upon arrival to the testing centre. After patients 
completed the visual velocity perception task in the clinically defined OFF state they either 
were given 300 mg of levodopa (unless their typical dosage was 100 mg or less, in which 
case they were given 200 mg of levodopa) or had their DBS device turned on to their usual 
stimulation levels depending on the patients primary PD therapy, then conducting the 
experiment in their ON medication state. It should be noted that a 1-hour break was given 
between the OFF and ON portion of the experiment. Furthermore, those using DBS did not 
take any Levodopa for their ON testing, preventing confounding results from therapeutic-
related task improvement.  Diagnostic assessment of Parkinson’s Disease motor severity 
(via the UPDRS part III [motor subsection]) was conducted in both ON and OFF states, 
with cognitive assessment (via the MoCA) being carried out before beginning the 
perceptual task. Also prior to testing (in the OFF state) visual diagnostic tests for smooth 
pursuit, saccades, and visual acuity (via reading tasks and the Snellen eye examination) 
were also conducted. Those that showed visual impairments (including visual 
hallucinations) and/or cognitive impairments (defined as MoCA score < 25) were omitted 
from the study. Furthermore, participants using PD medication other than Levodopa were 
excluded from study participation. It should be noted that a participant conducted all testing 
in a single session. 
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4.4.2 Testing Apparatus 
The computer-generated graphical tool used for the testing of visual velocity perception 
runs in the Matlab/Simulink platform, and was designed at the Canadian Surgical 
Techniques and Advanced Robotics lab.  Although the tool was used to test visual velocity 
perception, its design is flexible by nature, allowing it to be easily modified to test other 
visual perceptions. The visual velocity perception experiment was displayed on the LG 
Flatron W2242PM 22-inch monitor (resolution:  1680 x 1050).  The participant conducting 
the experiment was seated upright in the chair (that was adjusted in its height for maximum 
comfort) approximately 2 feet away from the monitor (Fig. 4.5).  The participant was tested 
in a room alone with the experimenter with minimal auditory and visual stimuli (apart from 
the task) in order to reduce attentional slips. 
4.4.3 Experiment 
A two-forced alternative choice perceptual experiment composed of 200 trials was carried 
out according to the method of constant stimuli for different thresholds as described by 
Gescheider [24].  Each trial began with a horizontally central white circle with a black, 
centred hole starting at the top of the computer monitor and moving at a constant velocity 
to the bottom of the monitor. Once reaching the bottom, the same circle again appeared at 
the top of the monitor, moving at the same constant velocity to the bottom. After this there 
was a gap of 2 seconds, followed by a solid white, horizontally centralized circle moving 
from the top to the bottom of the screen at a constant velocity in two successions. Thus, in 
each trial there were two circles each moving at a constant (but different) velocity, and the 
exposure the participant had to each circle was twice the duration of the circle moving from 
the top to bottom of the screen. For each trial the participant must answer verbally which 
circle they perceived to be moving the fastest (Fig. 4.5). There was no time constraint for 
the verbalization of their answer, thus movement impairments would not affect participant  
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Figure 16: Testing apparatus and velocity perception experiment. The LG Flatron 
W2242PM 22 inch (resolution 1680 x1050) computer monitor was used for testing, set up 
at a comfortable viewing position for the participant, who is sitting approximately 2 feet 
away from the monitor. The testing room has only the participant and experimenter, with 
excess stimuli (such as sounds, distracting visual) minimized. Illustrative examples of the 
velocity discrimination task shown on right, with the two squares representing the two 
objects which are compared. In each trial, the participant compares the constant vertical 
velocity of a circle with a hole to the constant vertical velocity of a solid circle.  The 
participant verbally answers which circle they perceived to be moving faster.  The exposure 
of each circle is moving from the top to the bottom of the screen twice, and the circles are 
separated by a 2 second waiting period.  Note the arrows are not present in experimental 
settings. 
 
success. In each trial one of two standard stimuli (10 cm/s or 25 cm/s) would be present 
and compared to one of 10 comparison velocities. The comparison values were chosen so 
that healthy individuals would always be able to differentiate the standard from the 
comparison differing the most in magnitude, and would answer correctly 50% of the time 
for the comparison value with the smallest magnitude difference from the standard (i.e.  the 
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participant was guessing).   Each comparison velocity was examined in 10 trials, with its 
order in relation to both the standard and other comparison values being randomized.  At 
the midway point of analysis (100th trial) a mandatory break was given to the participants; 
however, they were able to take as many breaks for as long as they desired throughout 
testing. It should be noted that control and de novo patients conducted the task once, 
however patients using DBS and levodopa conducted the experiment twice in both ON and 
OFF states. It is however unlikely that perceptual learning occurred, as the patients 
conducted the experiment only once for a given therapeutic state. Furthermore, neural 
learning for visual tasks is a process that occurs over long periods of time, with the one-
day testing session being too short for any meaningful learning [43, 44]. The psignifit 4.0 
third party Matlab psychometric assessment toolbox was used to calculate and create a 
cumulative Gaussian distribution foreach standard stimulus, allowing for perceptual 
quantification of each participant (Fig. 4.1). 
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Chapter 5  
5 Conclusions and Future Work 
5.1  Conclusions  
The purpose of this thesis was to explore certain visual perceptions in PD and develop 
disease diagnostic software. The perceptual modalities examined were not influenced by 
the motor system (which is impaired in PD), with PD disease patients ranging from early 
to late stages of the disease, and using levodopa, DBS, or no therapy for their PD, and 
compared to healthy controls. Following the objectives described in Chapter 1, the thesis 
was divided into three chapters, focusing on the temporal, displacement, and velocity 
perceptual modalities respectively, with the computer-generated graphical tool being used 
and validated for each perceptual modality. The goal of the work presented in this thesis 
was to develop a simple virtual reality tool that is able to use visual non-motor PD 
symptoms in the clinical assessment of  PD, of potential perceptual modalities that would 
function well with this tool, and to expand the knowledge of perceptual deficits occurring 
in PD. This work is the first step of the research goal to produce a tool capable of 
diagnosing and monitoring non-motor symptoms in PD. This takes into account the 
heterogeneous presentation of PD symptoms and considers the presence of non-motor 
symptoms before many motor symptoms. The work presented in this thesis provides a 
foundation for future work that will create a fully realized computational tool to accurately 
quantify and assess non-motor perceptions for use in neurological assessment. The overall 
conclusions from these chapters will be discussed in this section. 
 Chapter 2 studied visual temporal perception in the range of milliseconds and 
seconds. Our aim was to investigate temporal discrimination in PD without any motor 
influence (due to motor timing impairments), while further exploring the influence of the 
BG on timing and how therapies targeting the BG affect timing. For all patient groups, 
there were no impairments seen at the smaller tested magnitudes (using millisecond 
timing). However, all PD groups displayed significant impairments at the larger tested 
magnitudes (using interval timing). Neither levodopa nor DBS therapy led to significant 
improvements in timing abilities. Levodopa resulted in a strong trend towards impairing 
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timing processes and caused a deterioration in perceptual coherency according to Weber’s 
Law. It was shown that timing abnormalities in PD occur in the seconds range but does not 
extend to the millisecond range. Furthermore, observed timing deficits were shown to not 
be solely caused by motor deficiency. This provides evidence to support internal clock 
models involving the BG (among other neural regions) in interval timing, and cerebellar 
control of millisecond timing. 
 The investigation described in Chapter 3 studied allocentric visual displacement 
perception. Individuals with PD displayed significant perceptual impairments, with mid– 
to late–stage PD patients being particularly affected. The use of levodopa and DBS did not 
lead to statistically significant differences in the tested perceptual abilities of patients. 
However, DBS use showed a promising trend towards improvement in visual displacement 
perception. Regarding perceptual linearity analyzed via Weber’s Law, control group 
subjects closely followed a linear relationship, however, all tested PD groups displayed a 
significantly degraded linear relationship for perception of vision-based displacement in 
the OFF-therapy state.  Although Levodopa and DBS therapies did not cause improvements 
in the tested perception, their use did strengthen perceptual linearity relationships, 
suggesting a potential benefit to treatment use. Overall, these findings might suggest 
abnormal ventral occipitotemporal visual processing occurs in PD, which could contribute 
to freezing of gait, visuospatial deficits and abnormal object recognition. 
 Chapter 4 focused on the visual velocity perception of objects and investigated 
potential abnormalities that arise during PD and with the use of certain PD therapies. As 
with earlier chapters, PD patients displayed impairments with the accurate perception of 
visual velocity, affecting patients at early, mid, and late disease stages. These dysfunctions 
were only observed at the smaller tested standard stimulus (10 cm/s) however, with no 
differences in perceptual ability occurring between PD and control participants at the larger 
standard (25 cm/s).  Interestingly, levodopa appeared to have a detrimental effect on 
perceptual abilities of visual velocity, as significant impairments in perceptual sensitivity 
for patients ON levodopa (compared to being OFF levodopa) were observed. Furthermore, 
perceptual linearity (which was maintained in control and OFF therapy PD groups). The 
use of DBS did not however lead to alterations in velocity perception. These observations 
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highlight perceptual dysfunction in PD that has implications in navigational deficits and 
also highlights risks involving accurate speed perception such as the operation of 
automobiles that affects those with PD. 
 Throughout the work described in this thesis, a computer-generated graphical tool 
was used to analyze the perceptual ability for certain sensory modalities. The graphical tool 
proved to be capable of this task, with its flexible nature allowing for simple modifications 
to enable the analysis of various modalities. A primary goal of the toolbox development 
was for it to be simple to use, as well as easy to run on current computational devices. The 
clinical analysis of non-motor symptoms in PD is currently lacking, a substantial problem 
based on the disease’s heterogeneous nature. We hope the computer toolbox developed and 
used for the work in this thesis will be able to assist with the monitoring and management 
of PD, with it being used in both clinical and non-clinical settings (such as community or 
patients’ homes). In addition, we hope that the use of a similar device will assist with 
disease diagnosis and monitoring, allowing for more optimized treatment to improve the 
quality of lives of those suffering from PD. 
5.2 Future Work 
As previously noted, the computer-generated graphical tool can be easily operated, and its 
use has been demonstrated with the visual time, displacement, and velocity perceptual 
modalities. One direction of future work will be to explore different perceptual modalities 
in PD, including those using different sensory systems, such as the auditory system. This 
work will aim to provide insight into particular sensory modalities that prove to be ideal 
targets for the monitoring and diagnosis of PD. The analysis of sensory modalities studied 
in this thesis may also be performed with different parameters. For example, displacement 
perception (which was studied in a 2-dimensional allocentric fashion in this thesis) can be 
studied using a virtual reality headset (such as the oculus rift) to enable consideration of 
the perception of 3-dimensional depth displacement. Although this analysis also involves 
visual displacement perception, depth displacement relies on egocentric coordination, 
involving different neural processing, potentially providing increased sensitivity to 
disease-related sensory abnormalities. Furthermore, future work will increase focus on 
patients in the early stages of PD. As discussed throughout the thesis, several sensory 
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abnormalities arise in the early stages of PD, with some predating motor dysfunctions. In 
order to maximize the potential of a computer tool similar to the one used in the work 
described in this thesis, it should analyze some perceptions arising at the early disease 
stages, allowing for the tool to assist with disease diagnosis. Similarly, future work will 
seek sensory modalities that progress in severity with PD disease progression, to assist in 
monitoring of PD. A method of analysis that was outside of the scope of the current thesis 
is to assess an individual’s perceptual abilities across modalities (comparing their 
perceptual abilities collectively involving time, displacement and velocity tasks), and 
relating these abilities to motor functionality. Future work should assess the potential 
relationships between perceptual, motor, and integrative impairments that occur in PD. 
This can provide further insight in neural abnormalities occurring during the disease, and 
potentially lead to clinical assessment modalities or tests that are of increased sensitivity 
with regard to disease-based differences in ability. To further improve the clinical 
assessment viability of the work in this thesis, the graphical tool is planned for use in 
tandem with haptics-enabled robotic devices. These devices would further increase the 
diagnostic range of the computer-generated tool, as perceptions involving the motor system 
(such as proprioception and kinesthetics) could be incorporated in assessments. A future 
focus of great importance is the refining of the disease monitoring tool’s interface to allow 
for its use in a variety of settings. Though the implementation of the tool in clinical (and 
other) settings is not currently the primary focus, it is the ultimate focus of the research. By 
creating a user-friendly interface allowing for simple analysis and modification of the 
diagnostic test parameters, it will be possible to use the device to its maximal potential, and 
hopefully lead to improvement in PD management. Further work to increase accessibility, 
such as the development of a smartphone/tablet app will also be pursued in the future.  
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Appendices  
Appendix A: Ethics Approval (Levodopa and Control Participants) 
 
132 
 
Appendix B: Ethics Approval (DBS Participants) 
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Appendix C: Ethics Approval (de Novo Participants) 
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Appendix D: Letter of Informed Consent (LOI&C) for Levodopa Participants. 
Same LOI&C for Controls, except ON/OFF medication information is omitted. 
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Appendix E: LOI&C for DBS Participants 
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Appendix F: LOI&C for De Novo Participants 
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Appendix G: UPDRS Part III: Motor-Subsection 
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Appendix H: MoCA 
 
Use Body Text or Normal style for text in this section. 
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Appendix I: Snellen Eye Chart 
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